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Regulatory T (Treg) cells, a subset of CD4+ T cells whose development and 
function is specified by the transcription factor Foxp3, are essential for 
maintenance of immune homeostasis at steady state as well as during 
inflammatory and infections conditions.  Congenital deficiency of Treg cells in 
mice and humans as well as inducible ablation of Treg cells in adult mice 
results in rapid and lethal spontaneous T-cell driven autoimmunity.  The 
mechanisms by which Treg cells function, however, remain relatively 
unknown.  Here, we have attempted to elucidate some of these mechanisms 
and to provide a framework for understanding how suppressor function may 
be divided amongst distinct subpopulations of Treg cells.  We demonstrate 
that—in addition to its essential role in Treg cell differentiation in the thymus—
T cell receptor (TCR) expression in Treg cells is required for the Treg cell 
transition from a naïve to an effector state that occurs in the periphery and for 
continuous maintenance of suppressor function.  We further show—as a proof 
of principal—through generation of mice harboring a monoclonal population of 
Treg cells that TCR-dependent Treg cell function can be uncoupled to some 
extent from antigenic specificity and repertoire diversity.  Lastly, we explore 
how antigen-experienced effector Treg cells that have undergone an additional 
differentiation marked by stable expression of high amounts of the 
transcription factor T-bet selectively suppress TH1 autoimmunity and 
participate in TH1 responses to pathogenic challenge.  Together, these studies 
   
 
provide insight into how Treg cell function is elaborated and organized for 
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Biology of regulatory T cells 
The mammalian immune system constitutes the host’s defense against 
invading pathogens.  Upon infection, innate immune cells detect conserved 
components of bacteria, viruses, fungi, and multicellular parasites through an 
array of pattern recognition receptors (PRRs) and initiate the immune 
response through elaboration of cytokines and other effector molecules.  The 
adaptive arm of the immune system, coordinated in large part by CD4+ T cells 
that possess a vast array of randomly rearranged T cell receptors (TCRs) 
capable of recognizing non-conserved foreign proteins, amplifies the initial 
response, promotes pathogen clearance, and drives the rapid memory 
response that occurs upon secondary challenge (Zhu and Paul, 2010). 
 CD4+ T cell development in the thymus—through a process termed 
negative selection which forms the basis for “central” tolerance—ensures that 
the TCR repertoire is largely purged of frank self recognition in order to protect 
the host from unwanted T cell-driven autoimmune activation (Kappler et al., 
1987).  However, studies involving autoimmunity secondary to neonatal 
thymectomy together with the discovery of a subset of CD4+ T cells 
constitutively expressing the high affinity IL-2 receptor α-chain (CD25) that 
actively suppressed autoimmunity driven by CD4+CD25- cells indicated that 
another form of tolerance—peripheral, or dominant tolerance—also exists 
(Ohki et al., 1987; Sakaguchi et al., 1995).  Subsequent identification of 
mutations in the X-chromosome encoded Foxp3 gene in human 
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immunodysregulation, polyendocrinopathy, and enteropathy X-linked 
syondrome (IPEX) patients and scurfy mice that develop early onset lethal 
autoimmunity suggested Foxp3 to be the transcription factor responsible for 
coordinating the development and function of these immunosuppressive 
CD4+CD25+ regulatory T (Treg) cells (Bennett et al., 2001; Brunkow et al., 
2001; Wildin et al., 2001).  Genetic deletion of the Foxp3 gene has confirmed 
that Foxp3 is essential both for Treg cell development and for suppressive 
function in mature Treg cells, and genetic ablation of Foxp3+ Treg cells in adult 
mice demonstrated that Treg cells are continuously required throughout life for 
prevention of spontaneous autoimmunity (Gavin et al., 2007; Kim et al., 2007; 
Lin et al., 2007; Williams and Rudensky, 2007). 
 Distinct from conventional CD4+ T cells and consistent with their 
activated phenotype at steady state, Treg cells were shown to possess a TCR 
repertoire skewed towards self-recognition (Hsieh et al., 2004; Jordan et al., 
2001).  Indeed, TCR-mediated high affinity engagement with self in the thymus 
is critical for initiation of the Treg cell developmental program and for Foxp3 
induction (Gavin et al., 2007; Ohkura et al., 2012).  As compared to effector 
CD4+ T cells, Treg cells in secondary lymphoid organs express higher levels of 
TCR-induced genes, are more proliferative, and are enriched for effector-like 
CD44hiCD62Lo cells (Fisson et al., 2003).  TCR engagement in the periphery is 
important for Treg cell homeostasis and has been suggested to play a role in 
immunosuppressive function (Kim et al., 2009; Thornton and Shevach, 1998).  
However, whether TCR expression and specifically high affinity interactions 
with a diverse array of self antigens is (akin to Foxp3 expression) continuously 
required for Treg cell function remains to be resolved.  
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 Precisely how Treg cells suppress effector T cell activation and 
maintain immunological tolerance at steady state and during immune 
challenge is unknown.  It is notable, however, that Treg cells do not appear to 
utilize a unique suite of anti-inflammatory effector mechanisms but rather 
employ inhibitory factors—in an exaggerated manner—that are normally 
expressed by effector CD4+ T cell as part of their intrinsic activation-inhibition 
feedback loops.  This propensity to express anti-inflammatory factors (e.g., IL-
10, CTLA-4, CD25, CD73, CD39) is initiated in the thymus as part of a TCR 
stimulation- and cytokine-dependent developmental program that is 
subsequently solidified and maintained by Foxp3 (Gavin et al., 2007; Lin et al., 
2007; Ohkura et al., 2012).   
 It has also been noted that some activated Treg cells at steady state 
and during infectious challenge, in addition to Foxp3 can express the TH1, TH2, 
and TH17 CD4+ T cell master transcription factors T-bet, GATA-3, and RORγt, 
respectively, and it has been suggested that expression of these factors 
endows Treg cells with capacities to suppress and regulate distinct types of 
autoimmune and immune responses (Koch et al., 2009; Ohnmacht et al., 
2015; Rudra et al., 2012; Sefik et al., 2015; Wohlfert et al., 2011).  It remains 
unknown whether Treg cells further stably differentiate into TH1-, TH2-, and 
TH17-like subsets that each suppress a limited range of responses, or whether 
given that Treg cells already stably express their own master transcription 
factor Foxp3, expression of additional factors is transient and reversible, with 
any given Treg cell able to suppress any given type of immune response in a 
context-dependent manner.  
 
Overview of dissertation 
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This dissertation focuses on two questions outlined briefly above: the role of 
the TCR in Treg cell function, and the degree of compartmentalization of 
function within the TCR-activated Treg cell population. 
 First, we address the question of whether following TCR-dependent 
induction in the thymus, Treg cells continue to require their TCRs for 
suppressor function in vivo (Chapter 2).  We demonstrate that TCR expression 
by Treg cells is indispensable for their activation and function in the periphery, 
as mice constitutively lacking TCR expression on Treg cells phenocopy 
Foxp3KO mice lacking Treg cells.  Moreover, we show that inducible ablation of 
the TCR on mature Treg cells also results in Treg cell dysfunction that 
resembles inducible ablation of Treg cells.  TCR expression maintained the 
expression of a subset of genes comprising 25% of the activated Treg cell 
transcriptional signature. These results reveal a profound and continuous role 
for the TCR in the suppressor capacity of Treg cells. 
 Next, we describe our studies on the role of TCR repertoire specificity 
and diversity in TCR-dependent Treg cell function (Chapter 3).  Although in 
studies described in Chapter 2 we were able to demonstrate that TCR 
expression by Treg cells was continuously required for function, it remained 
unclear whether the same diverse TCR-mediated interactions between Treg 
cells and their cognate antigens which drove Treg cell induction in the thymus 
were also strictly required in the periphery for suppressor function (Bautista et 
al., 2009; Leung et al., 2009).  By generating mice harboring a monoclonal 
Treg cell population expressing a single Treg cell TCR recognizing an 
endogenous amount of antigen, we demonstrate that Treg cell function can to 
an extent be uncoupled from specificity and diversity, as replacement of the 
naturally diverse Treg cell TCR repertoire with this single TCR suppressed the 
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lethal autoimmunity that occurs in the absence of TCR on Treg cells.  The 
monoclonal Treg cell pool exhibited essentially a complete spectrum of TCR-
dependent gene expression, suggesting that TCR-dependent activation in the 
absence of appropriate specificity can still provide significant 
immunosuppressive function.   
 In studies described in Chapter 4 we explore features of TCR-activated 
effector Treg cells that express the TH1 master transcription factor, T-bet 
(Koch et al., 2009).  We assessed whether expression of this factor in Treg 
cells would be stable and indicative of a functionally distinct Treg cell subset, 
and thus reflect an essential Treg cell heterogeneity, or whether instead T-bet 
expression would be readily reversible, indicative of a more homogenous and 
labile effector Treg cell population.  We demonstrate that T-bet expression in 
Treg cells, induced at steady state and following infection, is highly stable 
even under non-TH1 inflammatory conditions and marks a discrete subset of 
Treg cells.  Although expression of T-bet itself in Treg cells was dispensable 
for their function, wholesale elimination of T-bet-expressing Treg cells resulted 
in severe TH1-type autoimmunity, demonstrating a major non-redundant 
immunosuppressive function carried out by a distinct subset of stably 
differentiated Treg cells. 
 In total, our studies contribute to understanding of some of the key 
mechanisms Treg cells employ and some of the features they adopt in order to 
mediate their essential immunosuppressive function.  Insights offered by our 
studies, directly or indirectly, may also facilitate future development of clinical 
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CHAPTER 2 




Foxp3+ regulatory T cells (Treg cells) maintain immunological tolerance, and 
their deficiency results in fatal multiorgan autoimmunity. Although heightened 
signaling via the T cell antigen receptor (TCR) is critical for the differentiation 
of Treg cells, the role of TCR signaling in Treg cell function remains largely 
unknown. Here we demonstrated that inducible ablation of the TCR resulted in 
Treg cell dysfunction that could not be attributed to impaired expression of the 
transcription factor Foxp3, decreased expression of Treg cell signature genes 
or altered ability to sense and consume interleukin 2 (IL-2). Instead, TCR 
signaling was required for maintaining the expression of a limited subset of 
genes comprising 25% of the activated Treg cell transcriptional signature. Our 




Regulatory CD4+ T cells that express the transcription factor Foxp3 have an 
essential role in maintaining immune tolerance (Josefowicz et al., 2012). In the 
thymus, increased affinity for engagement of the T cell antigen receptor (TCR) 
by immature CD4+ single-positive thymocytes is required for the initiation of a 
program for the differentiation of regulatory T cells (Treg cells) and induction of 																																																								
•	Adapted from Levine, A.G., Arvey, A., Jin, W., and Rudensky, A.Y. (2014). Continuous 
requirement for the TCR in regulatory T cell function. Nat. Immunol. 15, 1070-1078. 
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Foxp3 expression (Lee et al., 2012). As a consequence, Treg cells exported to 
the periphery exhibit a TCR repertoire skewed toward self-recognition (Hsieh 
et al., 2004; Hsieh et al., 2006). However, it remains unclear whether TCR 
signaling is needed to mediate the suppressive function of Treg cells in the 
periphery. 
 Treg cells exhibit impaired calcium flux, activation of the kinase Akt and 
phosphorylation of the kinase Erk upon TCR stimulation relative to that of 
conventional CD4+ T cells, and Foxp3 is known to potently repress at least 
some TCR-induced genes, as well as some genes encoding molecules 
involved in the TCR signaling pathway (Au-Yeung et al., 2010; Gavin et al., 
2002; Marson et al., 2007; Ouyang et al., 2012).  At the same time, Foxp3+ 
Treg cells have high basal expression of several cell surface molecules that 
are known to contribute to Treg cell function (such as CD25, CD39 and CTLA-
4), and the expression of these molecules in conventional CD4+ T cells is 
dependent upon TCR stimulation (Borsellino et al., 2007; Gavin et al., 2007; 
Lin et al., 2007; Pandiyan et al., 2007; Williams and Rudensky, 2007; Wing et 
al., 2008).  It is not known whether high-affinity interactions of the TCR with 
complexes of self peptide and major histocompatibility complex (MHC) class II 
contribute to constitutive expression of these genes and, consequently, to Treg 
cell function. 
 Treg cells, despite their intrinsically dampened response to TCR 
stimulation, acquire an activated phenotype and expand their populations in 
response to their cognate antigens in settings of activation of the immune 
system, such as infection and autoimmunity (Rosenblum et al., 2011; Shafiani 
et al., 2013). These observations indicate that recognition of self antigen helps 
maintain Treg cells of particular specificities and may potentiate their 
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suppressive ability during immunological challenge (Samy et al., 2005). 
Nevertheless, strict reliance on TCR expression for Treg cell activation, rather 
than 'preferential' activation of antigen-specific Treg cells, has not been 
demonstrated, nor has engagement of the TCR in vivo been shown to be 
required for Treg cell function in any context. 
 We used inducible genetic ablation of cell-surface TCR complexes to 
directly address the requirement for TCR expression in the 
immunosuppressive ability of Treg cells. Notably, the TCR was largely 
dispensable for Foxp3 expression, for lineage stability and for high expression 
of many signature genes in Treg cells. Nevertheless, these features were not 
sufficient to preserve Treg cell function or to prevent activation of the immune 
system. Loss of suppressor capacity in the absence of the TCR was not due to 
an impaired ability of Treg cells to gain access to interleukin 2 (IL-2) and, 
accordingly, administration of exogenous IL-2 failed to 'rescue' systemic 
autoimmunity. Instead, TCR expression was essential for the activation of 
Treg cells and for Treg cells to maintain expression of a limited set of genes 
found to be expressed almost exclusively in activated Treg cells. Among those 
genes, expression of the transcription factor IRF4 contributed to the optimal 
function and homeostasis of Treg cells. Our results demonstrate an essential 
role for the TCR in eliciting the suppressor function of differentiated Treg cells. 
 
Results 
Maintenance of Treg cell identity in the absence of the TCR 
To investigate the role of TCR signaling in Treg cell function, we crossed 
TracFL mice (which have a loxP-flanked allele encoding the TCR α-chain 
constant region (Cα or TCRα)) with Foxp3eGFP-Cre-ERT2 mice (with expression of 
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enhanced green fluorescent protein (eGFP) fused to a Cre recombinase–
estrogen-receptor-ligand-binding-domain protein from the 3′ untranslated 
region of Foxp3; called 'Foxp3Cre-ERT2' here) to achieve tamoxifen-inducible 
deletion of Trac specifically in Treg cells (Polic et al., 2001; Rubtsov et al., 
2010). In this model, Cre-induced loss of the conditional Trac allele upon 
tamoxifen administration eliminates TCRα expression, which prevents 
formation of heterodimers of TCRα and TCRβ (TCRαβ) at the cell surface. We 
administered tamoxifen via oral gavage on days 0 and 1 and analyzed mice on 
day 9. Allelic exclusion at the Trac locus in heterozygous TracFL/WTFoxp3Cre-
ERT2 mice yielded a small population (25%) of TCR-deficient (as assessed by 
flow cytometry (TCRβ−; called 'TCR−' here)) Treg cells (~25%), whereas in 
homozygous TracFL/FLFoxp3Cre-ERT2 mice, the majority of Treg cells (~60–70%) 
lacked cell surface TCRβ (Figure 2.1A). Although we cannot definitively 
exclude the possibility that few residual TCR complexes were present in 
minute amounts (below the detection limit of flow cytometric analyses), 
functional in vitro analyses confirmed loss of TCR crosslinking–dependent 
activation of TCR− Treg cells (Figure 2.2A-D). 
 Because binding sites for the transcription factors NFAT and c-Rel have 
been identified in the Foxp3 locus, and because TCR engagement–driven 
signaling via the transcription factor NF-κB is critical for induction of Foxp3 
expression, we speculated that the TCR might be essential for maintaining 
Foxp3 expression (Hsieh et al., 2012; Ruan et al., 2009; Zheng et al., 2010). 
However, Foxp3 expression was reduced only marginally in TCR− Treg cells in 
TracFL/WTFoxp3Cre-ERT2 mice and was not reduced at all in TCR− Treg cells in 
TracFL/FLFoxp3Cre-ERT2 mice, relative to its expression in TCR-expressing (as 
assessed by flow cytometry (TCRβ+; called 'TCR+' here)) Treg cells in the  
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Figure 2.1: Maintenance of Treg cell identity in the absence of the TCR. 
(A,B) Expression of TCRβ (A) and median fluorescence intensity (MFI) of 
Foxp3 (B) in CD4+Foxp3+ lymph node cells from 8- to 10-week-old 
TracWT/WTFoxp3Cre-ERT2 mice (WT/WT), TracFL/WTFoxp3Cre-ERT2 mice (FL/WT) 
and TracFL/FLFoxp3Cre-ERT2 mice (FL/FL) treated with tamoxifen by gavage on 
days 0 and 1 and analyzed on day 9. Gray shading (A), TCRβ staining on 
CD4−TCRβ− cells. (C) Flow cytometry of Foxp3+ T cells among CD4+YFP+ 
cells sorted to >99% purity from the spleens and lymph nodes of 
TracFL/WTFoxp3Cre-ERT2Rosa26YFP mice on day 13 following treatment with 
tamoxifen on days 0 and 1 and intraperitoneal injection of IL-2-neutralizing 
antibody (Anti-IL-2) or isotype-matched control antibody (Isotype) on days 4 
and 8. Numbers adjacent to outlined areas (left) indicate percent Foxp3+ cells 
among TCRβ+ cells (right) or TCRβ− cells (left). Each symbol (B,C (right)) 
represents an individual mouse; small horizontal lines indicate the mean. *P < 
0.05, **P < 0.01 and ***P < 0.001 (two-tailed unpaired t-test). Data are 
representative of two independent experiments with four or more (A,B) or two 
or more (C) mice per group in each. 
 
 









Figure 2.2. Treg cell surface phenotype and proliferative capacity in the 
absence of a functional TCR.  
(A) CD4+ eGFP+ TCRβ+ and TCRβ- cells were sorted from TracFL/WTFoxp3Cre-
ERT2 mice 9 days after tamoxifen treatment on days 0 and 1 (A), labeled with 
CellTrace Violet and plated in 96-well plates coated with anti-CD3ε (clone 
2C11) (B), anti-TCRβ (clone H57-597) (C) or PMA and Ionomycin (D) in the 
presence of 25U/mL IL-2 for 84 hours before analysis. All conditions were 
performed in triplicate wells with similar results. (E) Expression of Treg cell 
markers on TCRβ+ and TCRβ- CD4+Foxp3+ cells in lymph nodes of 
TracWT/WTFoxp3Cre-ERT2 (WT/WT), TracFL/WTFoxp3Cre-ERT2 (FL/WT) and 
TracFL/FLFoxp3Cre-ERT2 (FL/FL) mice. Gray histograms are gated on 
CD4+Foxp3- cells in TracWT/WTFoxp3Cre-ERT2 mice. (F) Percentages and 
absolute numbers of total Foxp3+ among CD4+ cells in spleens and lymph 
nodes of the indicated mice. (G) Gating strategy for analysis of TCRβ+ and 
TCRβ- cells among CD4+Foxp3+ lymph node cells. For (E-G), mice were 
analyzed on day 9 following tamoxifen treatment on days 0 and 1. Mice in (F-
H) are indicated as in (E). (H) BrdU incorporation vs. TCRβ expression on 
CD4+ eGFP+ cells sorted to >99% purity from pooled spleens and lymph 
nodes of the indicated mice on day 9 following tamoxifen treatment on days 0 
and 1 and i.p. injection of BrdU on day 8. Data is representative of two 
experiments with four or more mice per group each (E-G) or three experiments 
with two or more mice per group each (H). P-value in (F) was calculated using 
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same mice and in TracWT/WTFoxp3Cre-ERT2 mice (Figure 2.1B). Similarly, the 
expression of genes encoding several Treg cell signature molecules, including 
CD25, GITR, CD39 and CD73, was largely unaffected in TCR− Treg cells from 
both TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice (Figure 2.2E). 
These results indicated that in the steady state, continuous TCR-mediated 
recognition of self did not contribute substantially to Foxp3-dependent 
maintenance of expression of these genes (Wan and Flavell, 2007; Williams 
and Rudensky, 2007). In contrast, CTLA-4 expression was notably diminished 
in TCR− Treg cells in TracFL/WTFoxp3Cre-ERT2 mice, but not in TCR− Treg cells in 
TracFL/FLFoxp3Cre-ERT2 mice, relative to its expression in TCR+ Treg cells in 
TracWT/WTFoxp3Cre-ERT2 mice (Figure 2.2E). 
 The frequency and absolute number of Foxp3+ cells in the spleens and 
lymph nodes of TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice were 
unaltered compared with that in TracWT/WTFoxp3Cre-ERT2 mice (Figure 2.2F). 
However, to address the possibility that a portion of Treg cells completely lost 
Foxp3 expression upon ablation of the TCR and that these 'former' Treg cells 
were not accounted for in this experimental setup, we crossed 
TracFL/WTFoxp3Cre-ERT2 mice with mice that express the recombination reporter 
Rosa26YFP (with sequence encoding yellow fluorescent protein (YFP) 
expressed form the ubiquitous Rosa26 locus). We assessed the expression of 
TCRβ and Foxp3 in CD4+YFP+ cells sorted from the spleens and lymph nodes 
of TracFL/WTFoxp3Cre-ERT2Rosa26YFP mice on day 9 or 50 following tamoxifen 
administration on two consecutive days. YFP-expressing CD4+TCRβ− and 
CD4+TCRβ+ cell subsets contained similarly low frequencies of Foxp3− cells at 
both time points (data not shown). Furthermore, following in vivo neutralization 
of IL-2, a condition known to promote loss of Foxp3 expression (Rubtsov et al., 
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2010), in TracFL/WTFoxp3Cre-ERT2Rosa26YFP mice, populations of 
CD4+YFP+TCRβ− cells retained a higher percentage of Foxp3+ cells than did 
populations of CD4+YFP+TCRβ+ cells (Figure 2.1C). Together these data 
indicated that TCR signaling was dispensable for the maintenance of the Treg 
cell phenotype and lineage stability and, moreover, that TCR signaling drove 
the loss of Foxp3 when IL-2 amounts were limiting. 
 
Requirement for the TCR in effector differentiation of Treg cells 
Although the Treg cell phenotype was largely preserved upon ablation of the 
TCR, we observed relative enrichment for naive-like CD44loCD62Lhi cells 
among TCR− Treg cells in lymph nodes and spleens of TracFL/WTFoxp3Cre-ERT2 
and TracFL/FLFoxp3Cre-ERT2 mice (Figure 2.3A and Figure 2.2G). Treg cell 
proliferation is restricted almost exclusively to the CD44hi subset, and in part 
the enrichment we observed appeared to be a consequence of severely 
impaired proliferative capacity of CD44hi Treg cells in the absence of the TCR 
(Smigiel et al., 2014) (Figure 2.3B). The small population of TCR− Treg cells in 
TracFL/WTFoxp3Cre-ERT2 mice was predominantly nondividing: these cells 
showed minimal expression of the proliferation marker Ki67, failed to 
incorporate the thymidine analog BrdU over a 24-hour labeling period and 
contained the greatest frequency of CD44loCD62Lhi cells among all TCR+ or 
TCR− Treg cell populations in TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 
and TracFL/FLFoxp3Cre-ERT2 mice (Figure 2.3A,B and Figure 2.2H). In 
TracFL/FLFoxp3Cre-ERT2 mice, however, TCR− Treg cells exhibited considerable 
proliferative activity, albeit reduced relative to that of TCR+ Treg cells present 
in the same mouse (Figure 2.3B and Figure 2.2H). Increased Ki67 staining in 
CD44hi Treg cells was inversely correlated with a lower frequency of  














Figure 2.3. Requirement for the TCR in the differentiation and population 
expansion of Treg cells. 
(A,B) Expression of CD44 and CD62L on TCRβ+ or TCRβ− CD4+Foxp3+ 
lymph node cells (A) and of Ki67 on CD44hi CD4+Foxp3+ lymph node cells (B) 
isolated on day 9 from TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 and 
TracFL/FLFoxp3Cre-ERT2 mice treated with tamoxifen on days 0 and 1. (C) 
Expression of CD44 and CD62L on TCRβ+ or TCRβ− CD4+Foxp3+ lymph node 
cells in 2.5-week-old TracWT/WTFoxp3YFP-Cre, TracFL/WTFoxp3YFP-Cre and 
TracFL/FLFoxp3YFP-Cre mice (left), and expression of differentiation markers in 
those of the TracFL/WTFoxp3YFP-Cre mice. Numbers adjacent to outlined areas 
(left) indicate percent CD44hiCD62Llo cells; numbers in quadrants (right) 
indicate percent cells in each throughout. (D,E) Ki67 expression in TCRβ+ or 
TCRβ− CD4+Foxp3+  ymph node cells (D) and frequency of TCRβ+ or TCRβ− 
CD4+Foxp3+ cells among total CD4+ cells in the spleen and lymph nodes (LN) 
(E) of mice as in c. Each symbol (A,B,D,E (right)) represents an individual 
mouse. *P < 0.01 and **P < 0.001 (two-tailed unpaired t-test). Data are 
representative of two independent experiments with four or more mice per 
group in each (A,B) or three independent experiments with six or more mice 
per group (C) or are pooled from three independent experiments with six or 
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CD44loCD62Lhi cells among all TCR+ or TCR− Treg cell populations in mice of 
all three genotypes (Figure 2.3A,B). 
 To address the possibility that continuous peripheral differentiation of 
naive-like Treg cells into CD44hi cells was impeded in the absence of TCR 
expression and that such a differentiation block contributed to the 
predominantly CD44loCD62Lhi phenotype of TCR− Treg cells, we bred TracFL 
mice with Foxp3YFP-Cre mice (which express a fusion of Cre and YFP from the 
3′ untranslated region of Foxp3) to induce ablation of the TCR in newly 
generated, 'naive' Treg cells (Fisson et al., 2003; Rubtsov et al., 2008). We 
reasoned that if the TCR were critical for the effector differentiation of Treg 
cells in the periphery, TCR− Treg cells in these mice would retain a 
CD44loCD62Lhi naive-like phenotype. 
 Immature HSAhi CD4+Foxp3+ cells in the thymi of TracFL/FLFoxp3YFP-Cre 
mice had cell surface expression of TCR complexes similar to that in their 
wild-type counterparts; more mature HSAloCD4+Foxp3+ thymocytes showed 
only slightly reduced TCR expression (Figure 2.4A). Among Foxp3+ cells 
present in the spleens and lymph nodes of TracFL/WTFoxp3YFP-Cre mice, ~5–
15% were TCRβ−, whereas ~80% of Foxp3+ cells in TracFL/FLFoxp3YFP-Cre mice 
lacked surface TCRβ expression (Figure 2.3E and Figure 2.4B). We again 
observed a slight decrease in the amount of Foxp3 protein in the TCR− Treg 
cells in TracFL/WTFoxp3YFP-Cre mice, but not in TracFL/FLFoxp3YFP-Cre mice, while 
expression of Treg cell signature genes was variably affected in the TCR− 
Treg cell populations in both mouse strains relative to expression in TCR+ 
Treg cells in TracWT/WTFoxp3YFP-Cre, TracFL/WTFoxp3YFP-Cre and 
TracFL/FLFoxp3YFP-Cre mice (Figure 2.4C,D). 
 










Figure 2.4. Constitutive ablation of the TCR in TracFL/FLFoxp3YFP-Cre mice 
impairs Treg cell population expansion and precipitates early-onset 
autoimmunity.  
(A-C) TCRβ expression on CD4+Foxp3+ cells in the thymi (A) and lymph 
nodes (A,B) of 2.5 wk old mice, and Foxp3 median fluorescence intensity 
(MFI) in CD4+Foxp3+ lymph node cells (C) in 2.5 wk old TracWT/WTFoxp3YFP-Cre 
(WT/WT), TracFL/WTFoxp3YFP-Cre (FL/WT) and TracFL/FLFoxp3YFP-Cre (FL/FL) 
mice. (D) Representative expression of Treg markers on the indicated TCRβ+ 
and TCRβ- populations. Gray histogram is gated on CD4+Foxp3- cells in 
TracWT/WTFoxp3YFP-Cre mice. (E,F) Activation status (E), spleen and lymph 
node cell numbers, and percent cytokine producers in the spleen (F) of 
CD4+Foxp3- and CD8+ cells. (G) Absolute numbers of TCRβ+ and TCRβ- 
CD4+Foxp3+ cells in 2.5 week old TracWT/WTFoxp3YFP-Cre (WT), 
TracFL/WTFoxp3YFP-Cre (Het), and TracFL/FLFoxp3YFP-Cre (KO) mice. (H) Absolute 
numbers of CD4+TCRβ+Foxp3- (left) and TCRβ+ and TCRβ- CD4+Foxp3+ cells 
(right) in liver (top) and lungs (bottom) of indicated mice. Data in (B-E) are 
representative of three experiments with a total of six or more mice per group. 
Data in (F,G) are aggregated from three experiments with a total of six or more 
mice per group. Data in (A) and (H) are representative of two experiments with 
three or more mice per group each. ***, P < 0.001; **, P < 0.01; *, P < 0.05. P-
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 Despite their generally intact Treg cell surface phenotype, nearly all 
TCR− Treg cells in healthy TracFL/WTFoxp3YFP-Cre mice had a naive-like 
CD62LhiCD44lo phenotype and lacked expression of all Treg cell differentiation 
markers tested, including KLRG1, CD103 and CXCR3 (Figure 2.3C and data 
not shown). Notably, we also observed this pattern under severe inflammatory 
conditions in TracFL/FLFoxp3YFP-Cre mice, which were moribund by 3 weeks of 
age (Figure 2.3C and Figure 2.4E,F). The lack of CD44hi cells among TCR− 
populations in TracFL/WTFoxp3YFP-Cre and TracFL/FLFoxp3YFP-Cre mice correlated 
with the decreased proliferation and markedly diminished frequency and 
number of TCR− Treg cells relative to that of TCR+ Treg cells in the same mice 
and in TracWT/WTFoxp3YFP-Cre mice; this pattern was evident in lymph nodes 
and was particularly pronounced in the spleen and other tissues such as the 
liver and lungs (Figure 2.3D,E and Figure 2.4G,H). Together these data were 
consistent with an absolute requirement for TCR expression, the loss of which 
could not be compensated for even in conditions of extreme activation of the 
immune system, for the peripheral effector differentiation of naive-like Treg 
cells and acquisition of an activated CD44hi phenotype. 
 
TCR-dependent effector function of mature Treg cells 
Foxp3 expression and Treg cell population expansion are facilitated by 
signaling via the receptor for IL-2 (IL-2R) (Fontenot et al., 2005; Tang et al., 
2008; Webster et al., 2009). The increase in Foxp3 protein expression and 
proliferative activity of TCR− Treg cells in TracFL/FLFoxp3Cre-ERT2 mice 
compared with that in such cells in TracFL/WTFoxp3Cre-ERT2 mice led us to 
suspect that ablation of TCR expression, even on mature Treg cells, might 
precipitate activation of the immune system and elevate the production of IL-2 
  24 
 
and other cytokines by activated CD4+ T cells. Indeed, analysis of 
TracFL/FLFoxp3Cre-ERT2 mice treated twice with tamoxifen and analyzed on day 
9 after treatment revealed increased percentages of CD44hi T cells and 
increased numbers of IL-2–producing CD4+ T cells compared with that of 
tamoxifen-treated TracWT/WTFoxp3Cre-ERT2 and TracFL/WTFoxp3Cre-ERT2 mice 
(data not shown). 
 To more rigorously investigate the role of TCR expression in mature 
Treg cell function, we administered four doses of tamoxifen to mice (on days 
0, 3, 7 and 10) to maximize Cre-ERT2–mediated recombination. On day 13, 
we noted loss of TCR expression in ~75–80% of Treg cells 
inTracFL/FLFoxp3Cre-ERT2 mice and ~25–30% of Treg cells in TracFL/WTFoxp3Cre-
ERT2 mice (Figure 2.5A,B). Despite the normal or even increased frequency of 
total Foxp3+ cells in the lymph nodes and spleens of TracFL/FLFoxp3Cre-ERT2 
mice, we found elevated numbers of CD4+Foxp3− and CD8+ T cells in the 
lymph nodes of these mice and a higher frequency of CD44hiCD4+ and CD8+ T 
cells in their lymph nodes and spleens (Figure 2.5C,D). CD8+ T cells from 
TracFL/FLFoxp3Cre-ERT2 mice produced more interferon-γ (IFN-γ), and CD4+ T 
cells from these mice produced more IFN-γ, IL-2, IL-4, IL-13, IL-5 and IL-17, 
than did T cells from TracWT/WTFoxp3Cre-ERT2 and TracFL/WTFoxp3Cre-ERT2 mice 
(Figure 2.5E and data not shown). 
 The activation of the immune system in TracFL/FLFoxp3Cre-ERT2 mice was 
milder than that resulting from complete depletion of Treg cells in Foxp3DTR 
mice, which express the human diphtheria toxin receptor (DTR) concomitantly 
with Foxp3 (Kim et al., 2007). Thus, it was possible that the large number of 
TCR− Treg cells in TracFL/FLFoxp3Cre-ERT2 mice retained measurable TCR-
independent suppressor ability and were still capable of immunoregulation.  




Figure 2.5. TCR-dependent effector function of mature Treg cells in adult 
mice. 
(A) Expression of Foxp3 and TCRβ by CD4+ cells in the lymph nodes of 
TracWT/WTFoxp3Cre-ERT2,TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice 
on day 13 following tamoxifen treatment on days 0, 3, 7 and 10. Numbers 
adjacent to outlined areas indicate percent Foxp3+TCRβ+ cells (right) or 
Foxp3+TCRβ− cells (left). (B) Frequency of TCRβ+ Foxp3+ cells among splenic 
and lymph node CD4+ cells in TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 
and TracFL/FLFoxp3Cre-ERT2 mice, and of total Foxp3+ cells among CD4+ cells for 
each genotype (Total Foxp3+). (C–E) Number (C), CD44 expression (D) and 
cytokine production (E) of CD4+ Foxp3− or CD8+ T cells in the spleen (C–E) 
and lymph nodes (C,D) of mice as in A. Each symbol (C–E) represents an 
individual mouse; small horizontal lines indicate the mean. NS, not significant 
(P ≥ 0.05); *P < 0.005 and **P ≤ 0.0001 (two-tailed unpaired t-test). Data are 
representative of three experiments with three mice or more per group in each 
(A) or are pooled from three experiments with nine or more per group (B–E; 
error bars (B), mean ± s.e.m.). 
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Alternatively, the small population of remaining TCR-sufficient Treg cells in 
these mice might have limited, to some degree, the activation of effector T 
cells and the associated autoimmunity. To examine these possibilities, we 
attempted to reduce the proportion of Treg cells among CD4+ cells in Foxp3DTR 
mice to approximate the frequency of residual TCR-sufficient Treg cells in 
TracFL/FLFoxp3Cre-ERT2 mice following four doses of tamoxifen (Tian et al., 
2011). We reasoned that if TCR− Treg cells were capable of substantial 
suppression, autoimmunity in Foxp3DTR mice subjected to only partial 
depletion of Treg cells would be more severe than that in TracFL/FLFoxp3Cre-
ERT2 mice. Injection of diphtheria toxin depletes mice of Treg cells within 24 h, 
whereas tamoxifen-induced, Cre-ERT2–mediated recombination progressively 
increases over a 4-day period (data not shown).  Therefore, we treated 
Foxp3DTR, TracWT/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice with 
diphtheria toxin 4 d after their first dose of tamoxifen to account for the time 
needed for complete Cre-ERT2–mediated deletion of Trac (we administered 
both taximofen and diphtheria toxin to all genotypes; Figure 2.6A,B). Partial 
depletion of the Treg cell compartment in Foxp3DTR mice resulted in activation 
and cytokine production of CD4+Foxp3− T cells grossly similar to that observed 
in TracFL/FLFoxp3Cre-ERT2 mice with populations of TCR-sufficient Treg cells of a 
similar or even larger size (Figure 2.6B-D). Together these results 
demonstrated that Treg cells required continuous TCR expression for the 
effective elaboration of their suppressor function, and suggested that TCR− 
Treg cells, which were abundant in TracFL/FLFoxp3Cre-ERT2 mice, were largely 
devoid of detectable suppressor ability. 
 
TCR− Treg cell dysfunction is not secondary to impaired IL-2R signaling 


















Figure 2.6. Partial depletion of Treg cells in Foxp3DTR mice recapitulates 
activation of the immune system in TracFL/FLFoxp3Cre-ERT2 mice.  
(A) Experimental protocol. TracWT/WTFoxp3Cre-ERT2 (TracWT/WT), 
TracFL/FLFoxp3Cre-ERT2 (TracFL/FL) and Foxp3DTR mice were gavaged with 
tamoxifen on days 0, 3, 7 and 10. Foxp3DTR mice were injected i.p. with PBS, 
0.065ug DT, or 0.1ug DT and TracWT/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-
ERT2 mice were injected with 0.065ug DT on days 4, 7 and 10. (B) Percent 
TCRβ+Foxp3+ cells among CD4+ cells in spleens of TracWT/WTFoxp3Cre-ERT2 
and TracFL/FLFoxp3Cre-ERT2 (black squares) and Foxp3DTR (gray squares) mice. 
Total Foxp3+ cells among CD4+ cells in TracFL/FLFoxp3Cre-ERT2 mice are shown 
as white squares. (C,D) Activation of (C) and cytokine production by (D) 
splenic CD4+Foxp3- cells. Fold-changes are shown. All data are representative 
of two experiments with four or more mice per group each. ***, P < 0.001; **, P 
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We considered that the apparent loss of suppressive ability of Treg cells in the 
absence of the TCR might be an indirect consequence of impaired ability to 
localize in a TCR- and antigen-dependent manner to sites of CD4+ T cell  
 activation and to thereby acquire IL-2, a cytokine known to be critical for the 
function and homeostasis of Treg cells. This would explain the decreased 
expression of Foxp3 and minimal proliferation of TCR− Treg cells in healthy 
TracFL/WTFoxp3Cre-ERT2 mice, in which IL-2 amounts were not elevated and 
would not be able to partially remedy these defects (Zou et al., 2012). 
 However, direct ex vivo analysis of phosphorylation of the transcription 
factor STAT5, which occurs downstream of IL-2 signaling in Treg cells, 
showed that in the spleen and lymph nodes of both TracFL/WTFoxp3CreERT2 and 
TracFL/FLFoxp3Cre-ERT2 mice, the proportion of phosphorylated STAT5 in TCR− 
Treg cells was at least equivalent to that in TCR+ Treg cells (Figure 2.7A and 
data not shown). In TracFL/FLFoxp3Cre-ERT2 mice, TCR− Treg cells had more 
phosphorylated STAT5 than did TCR+ Treg cells; this mirrored their expression 
of CD25 and CD62L, which remained high on TCR− cells but was decreased 
on the residual activated TCR+ Treg cells present in these mice (Figure 2.3A 
and Figure 2.7A and Figure 2.2E,G). These results were consistent with the 
observation that Treg cells that contain phosphorylated STAT5 are found 
mainly in the CD62LhiCD44lo (and CD25hi) subset of Treg cells; in contrast to 
the activated CD44hiCD62Llo (and CD25int) Treg cell subset, this group of cells 
has been reported to rely on IL-2R signaling rather than engagement of 
costimulatory receptors for their maintenance (Smigiel et al., 2014). 
 In vitro analysis confirmed that lack of TCR expression did not 
substantially influence the phosphorylation of STAT5 in response to IL-2, nor 
did it impair the ability of Treg cells to capture and deplete IL-2 from culture  
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Figure 2.7. TCR expression by Treg cells is dispensable for IL-2R 
signaling in vivo. 
(A) Phosphorylation of STAT5 at Tyr694 (p-STAT5(Y694)) in TCRβ+ or TCRβ− 
CD4+Foxp3+ lymph node cells from TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-
ERT2 and TracFL/FLFoxp3Cre-ERT2 mice on day 9 following tamoxifen 
administration on days 0 and 1. Numbers adjacent to outlined areas indicate 
percent CD4+ Foxp3+ cells with phosphorylated STAT5. (B) Median 
fluorescence intensity of Foxp3 in TCRβ+ or TCRβ− Foxp3+ cells (top) and 
frequency of TCRβ+ or TCRβ− Foxp3+ cells among CD4+ cells (bottom) in the 
lymph nodes of TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 and 
TracFL/FLFoxp3Cre-ERT2 mice on day 13 following tamoxifen treatment on days 0, 
3, 7 and 10 and intraperitoneal injection of IL-2-neutralizing or isotype-
matched contol antibody on days 4 and 8. Numbers above plots indicate 
comparison of results obtained for mice treated with isotype-matched control 
antibody relative to those for mice treated with anti-IL-2. Each symbol (B) 
represents an individual mouse; small horizontal lines indicate the mean. *P < 
0.05, **P < 0.01 and ***P < 0.001 (two-tailed unpaired t-test). Data are 
representative of three experiments involving a total of three or more mice per 
group (a) or of two experiments with two or more mice per group in each (B). 
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media (Figure 2.8A,B), which suggested that in the absence of TCR 
expression, Treg cell–mediated deprivation of IL-2 might not be an important 
mechanism of immunosuppression. Furthermore, treatment of 
TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice 
with neutralizing antibody to IL-2 (anti-IL-2) or isotype-matched control 
antibody had a similar effect on TCR+ and TCR− Treg cells, reducing Foxp3 
expression and lowering the frequency of Foxp3+ cells among total CD4+ cells 
(Figure 2.7B). Together these data suggested that TCR− Treg cells efficiently 
captured IL-2 during activation of the immune system and at steady state. It 
remains to be determined what signal(s) drove the proliferation of TCR− Treg 
cells selectively in diseased TracFL/FLFoxp3Cre-ERT2 mice. However, we 
observed increased expression of the costimulatory molecules CD80 and 
CD86 on lymph node dendritic cells (DCs) in TracFL/FLFoxp3Cre-ERT2 mice, and 
activated DCs were able to induce limited proliferation of TCR− Treg cells in 
vitro (Figure 2.8C,D). 
 Finally, the administration of complexes of IL-2 and anti-IL-2 to 
TracFL/FLFoxp3Cre-ERT2 mice did not measurably diminish the activation or 
lymphoproliferation of effector T cells caused by loss of TCR expression in 
Treg cells (Figure 2.9). Conversely, IL-2 depletion did not further exacerbate 
autoimmunity (data not shown). Notably, this was the case despite a 1.5-fold 
population expansion of TCR− Treg cells, but not of TCR+ Treg cells, following 
IL-2 administration (probably a consequence of higher CD25 expression and 
heightened IL-2 responsiveness in TCR− Treg cells) and a reduction of over 
twofold in TCR− Treg cells following depletion of IL-2 (Figure 2.7B and Figure 
2.9B). These observations further confirmed that TCR− Treg cells, even when 
present in elevated numbers, had minimal suppressive ability. Together these  
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Figure 2.8. Maintenance of TCR-deficient Treg cell responsiveness to IL-
2 and proliferation in the presence of activated DCs in vitro.  
(A) p-STAT5 was assessed in eGFP+ (Treg) cells among bulk CD4+ cells 
purified on day 9 from TracFL/WTFoxp3Cre-ERT2 mice treated with tamoxifen on 
days 0 and 1, stained for CD4 and TCRβ, and cultured with increasing 
concentrations of IL-2 for 20 minutes before fixation. Data is representative of 
two experiments with a total of two mice. (B) In vitro IL-2 capture assay. 
TracFL/WTFoxp3Cre-ERT2 mice were administered tamoxifen on days 0 and 1, 
and on day 9 CD4+ eGFP+TCRβ+, CD4+ eGFP+TCRβ-, and CD4+TCRβ+ eGFP 
cells were sorted and cultured in media with increasing concentrations of IL-2. 
PE median fluorescence intensity (MFI) directly correlates with IL-2 remaining 
in the media at the time of analysis. (C) CD80 expression on DC populations in 
lymph nodes of TracWT/WTFoxp3Cre-ERT2 (black lines, left, and white circles, 
right) and TracFL/FLFoxp3Cre-ERT2 (red lines, left, and black circles, right) mice 
on day 13 following tamoxifen administration on days 0, 3, 7 and 10. (D) In 
vitro proliferation of Treg cells was assessed as follows: CD4+ eGFP+ cells 
were sorted on day 9 from TracFL/WTFoxp3Cre-ERT2 mice treated with tamoxifen 
on days 0 and 1, labeled with CellTrace Violet and cultured for 84 hrs with IL-2 
in the presence or absence of DCs with or without LPS. Cells were stained for 
CD4, TCRβ and Foxp3 for analysis. All conditions were performed in triplicate 
with similar results. **, P < 0.001; *, P = 0.002. P-values were calculated using 
a two-tailed unpaired t-test. 
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Figure 2.9. IL-2–anti-IL-2 complexes do not 'rescue' autoimmunity in 
TracFL/FLFoxp3Cre-ERT2 mice.  
(A) Schematic of the experimental setup. (B) Percent TCRβ+Foxp3+ (black 
squares) and total Foxp3+ (white squares) cells among CD4+ cells in lymph 
nodes of TracWT/WTFoxp3Cre-ERT2 (WT/WT) and TracFL/FLFoxp3Cre-ERT2 (FL/FL) 
mice treated with IL-2-anti-IL-2 complexes (IL2-c) or PBS. (C,D) CD4+ T cell 
activation (C) and cytokine production (D) in the spleens of the indicated mice, 
as in (B). NS, not significant (P ≥ 0.05); **, P < 0.01; *, P < 0.05. P-values were 
calculated using a two-tailed unpaired t-test. 
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results indicated that neither TCR-dependent interactions with antigen-
presenting cells nor continuous TCR-mediated localization within lymphoid 
organs were required for Treg cells to acquire IL-2, and that Treg cell 
dysfunction in the absence of the TCR could not be attributed to altered IL-2R 
signaling. 
 
TCR expression promotes Treg cell adhesive properties in vitro 
The in vitro suppressive ability of Treg cells requires engagement of the TCR 
(Kim et al., 2009; Thornton and Shevach, 1998). This might involve pathways 
independent of the catalytic activity of the signaling kinase Zap70, which is 
essential for the effector function of conventional T cells, but dependent on 
membrane-proximal inside-out activation of integrins and subsequent 
enhancement of the interaction of Treg cells with antigen-presenting cells (Au-
Yeung et al., 2010). To address this possibility, we cultured TCR+ or TCR− 
Treg cells isolated from TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 or 
TracFL/FLFoxp3Cre-ERT2 mice with DCs and assessed the formation of DC–Treg 
cell conjugates. We did not detect any difference in conjugate formation 
between DCs and TCR+ or TCR− Treg cells following 30 min of incubation 
(data not shown). However, following overnight culture, TCR− Treg cells 
isolated from TracFL/WTFoxp3Cre-ERT2 or TracFL/FLFoxp3Cre-ERT2 mice were less 
efficient than were TCR+ Treg cells at forming conjugates with DCs (3.7% of 
TCR− Treg cells compared with 7.5% of TCR+ Treg cells; Figure 2.10A). 
Conjugate formation was unaffected by the presence or absence of MHC class 
II molecules on DCs (Figure 2.10A), which might indicate that the greater 
adhesion of TCR+ Treg cells than of TCR− Treg cells in this assay was not a 
result of interactions between TCR and MHC class II and might have been a  




Figure 2.10. Altered in vitro conjugate formation between Treg cells and 
DCs in the absence of the TCR.  
(A) Conjugate formation was assessed by culturing 6 x104 CellTrace Violet-
labeled DCs overnight with 104 CFSE-labeled TCR+ or TCR- Treg cells in the 
presence of 500 U/mL IL-2. Percent CellTrace Violet+ cells among CFSE+ cells 
is plotted. TCR+ cells and DCs were cultured in the presence of 2.5 ug/mL 
Concanavalin A (ConA) as a positive control. (B) Assessment of LFA-1 
expression on CD44hiCD62Llo vs. CD44loCD62Lhi CD4+Foxp3+ and Foxp3- 
cells by flow cytometric analysis of CD11a (ITGAL) expression. *, P < 0.01. P-
value in (A) was calculated using a two-tailed unpaired t-test. 
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consequence of the overall heightened activation status of TCR+ Treg cells 
relative to that of TCR− Treg cells. As expression of the integrin LFA-1 was 
higher on CD44hi Treg cells than on CD44loCD62Lhi Treg cells (Figure 2.10B), 
it is possible that greater conjugate formation by TCR+ Treg cells, which show 
greater enrichment for CD44hi cells than do TCR− Treg cells, was due at least 
in part to increased expression of this integrin. Further work is needed to 
determine precisely how engagement of the TCR in vivo affects signaling 
pathways to modulate the adhesive properties of Treg cells. However, our 
results indicated that TCR expression contributed to optimal contact-
dependent interactions between Treg cells and antigen-presenting cells, which 
might support TCR-dependent immunosuppressive function. 
 
TCR modulation of the effector Treg cell transcriptional signature 
To explore whether TCR signals, apart from influencing Treg cell adhesion, 
might drive transcriptional events to 'license' suppressor function in vivo, we 
analyzed the gene expression of TCR+ and TCR− Treg cells. Flow cytometry 
showed that loss of TCR expression had a stronger effect on effector-like 
CD44hiCD62Llo Treg cells than on naive-like CD44loCD62Lhi Treg cells (data 
not shown). This prompted us to investigate the gene-expression profiles of 
these two populations separately in the TCR+ or TCR− Treg cell populations 
isolated from healthy TracFL/WTFoxp3Cre-ERT2 mice (to avoid confounding effects 
of activation of the immune system). We found that 155 genes were 
downregulated by at least twofold and only five genes were upregulated by 
that amount in effector-like CD44hiCD62Llo TCR− Treg cells relative to their 
expression in CD44hiCD62Llo TCR+ Treg cells (Figure 2.11A). 16 genes were 
downregulated in the naive-like CD44loCD62Lhi TCR− Treg cells relative to  








Figure 2.11. TCR signaling maintains the effector Treg cell 
transcriptional signature. 
(A) Genes expressed differently in CD44hiCD62Llo versus CD44loCD62Lhi 
TCRβ+ Treg cells plotted against those expressed differently in CD44hiCD62Llo 
TCRβ− versus CD44hiCD62Llo TCRβ+ Treg cells (top) or CD44loCD62Lhi TCRβ− 
versus CD44loCD62Lhi TCRβ+ Treg cells (bottom) among subpopulations 
sorted by flow cytometry on day 14 from TracFL/WTFoxp3Cre-ERT2 mice treated 
with tamoxifen on days 0, 1 and 3; numbers in plots indicate genes up-
regulated (blue) or down-regulated (red) by twofold or more in the absence of 
the TCR (q < 0.01). (B) Genes down-regulated twofold or more in 
CD44hiCD62Llo TCRβ− Treg cells relative to their expression in 
CD44hiCD62Llo TCRβ+ Treg cells (TCR) among those up-regulated twofold or 
more in CD44hiCD62Llo Treg cells relative to their expression in CD44loCD62Lhi 
Treg cells (Up) (left), and genes up-regulated twofold or more in CD44hiCD62Llo 
Treg cells relative to their expression in CD44loCD62Lhi Treg cells (Up) among 
those down-regulated twofold or more in CD44hiCD62Llo TCRβ− Treg cells 
relative to their expression in CD44hiCD62Llo TCRβ+ Treg cells (TCR) (right). 
(C) Cumulative distribution function plot of TCR-dependent genes plotted 
against all genes expressed differently in Foxp3GFP-KO T cells versus Foxp3+ 
CD4+ T cells. P < 10−20 (two-sample Kolmogorov-Smirnov test). (D) 
Expression patterns of TCR-dependent genes encoding transcription factors, 
cell surface molecules and secreted molecules in Treg cells. Data are 
representative of one experiment with two or more replicates with five or more 
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their expression in CD44loCD62Lhi TCR+ Treg cells (all of these were also 
downregulated in CD44hiCD62Llo TCR− vs. CD44hiCD62Llo TCR+ Treg cells), 
whereas one gene was upregulated (Figure 2.11A). Some 535 genes showed 
higher expression (twofold or greater) in effector-like CD44hiCD62Llo TCR+ 
Treg cells than in naive-like CD44loCD62Lhi TCR+ Treg cells, and the 
expression of 136 of these (25%) was TCR dependent (Figure 2.11B). 
Notably, 127 of the 155 genes (82%) downregulated in the absence of the 
TCR in CD44hiCD62Llo Treg cells showed at least twofold higher expression in 
effector-like Treg cells than in naive-like Treg cells (Figure 2.11B). 
 Foxp3 has been proposed to solidify and amplify a transcriptional 
program initiated in Treg cell precursors by engagement of the TCR (Gavin et 
al., 2007; Lin et al., 2007; Ohkura et al., 2012; Samstein et al., 2012). We 
compared the expression of the 155 genes identified above as being 
maintained by the TCR in Treg cells (called 'TCR-dependent genes' here) to 
the expression of Foxp3-dependent genes, identified as being upregulated in 
wild-type Treg cells relative to their expression in eGFP+ T cells from 
Foxp3GFP-KO mice, which express eGFP from a Foxp3-null allele (Samstein et 
al., 2012). We found that substantially more of the TCR-dependent genes than 
all genes were also Foxp3 dependent (Figure 2.11C). These observations 
suggested that the TCR-driven transcriptional program in Treg cells was 
enhanced by Foxp3 expression, but that Foxp3 alone was not sufficient to 
maintain the full transcriptional signature of effector Treg cells. 
 Examination of the TCR-dependent genes identified several 
transcription factors that were upregulated in TCR+ CD44hiCD62Llo Treg cells 
relative to their expression in TCR− CD44hiCD62Llo, TCR+ CD44loCD62Lhi and 
TCR− CD44loCD62Lhi Treg cells, including NFATc1, c-Rel, Bcl-6 and IRF4 
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(Figure 2.11D); published data have shown that Bcl-6 and IRF4 are important 
for the differentiation and function of effector Treg cells (Cretney et al., 2011; 
Sawant et al., 2012; Zheng et al., 2009). Of the 155 TCR-dependent genes, 
we identified only one adhesion molecule–encoding gene (Vcam1) whose 
expression was upregulated in CD44hiCD62Llo Treg cells relative to its 
expression in CD44loCD62Lhi Treg cells in a manner that depended on TCR 
expression (Figure 2.11D). Genes encoding several other potential effector 
molecules were also upregulated in CD44hiCD62Llo Treg cells relative to their 
expression in CD44loCD62Lhi Treg cells, in a TCR-dependent manner, 
including those encoding IL-1R2 (a decoy receptor for IL-1); the 
immunoinhibitory molecules CD83, CD200 and LAG-3; IL-10; and EBI3 (a 
subunit of the cytokines IL-27 and IL-35) (Collison et al., 2007; Colotta et al., 
1993; Hall et al., 2012; Huang et al., 2004; Petermann et al., 2007; Reinwald 
et al., 2008; Rubtsov et al., 2008). In addition, the chemokine-encoding genes 
Cxcl10 and Ccl1, as well as Ccr8 (which encodes the receptor for CCL1), were 
significantly downregulated in TCR− Treg cells relative to their expression in 
TCR+ Treg cells, which suggested that Treg cells might signal each other 
through the expression of chemokines and their corresponding receptors or 
might recruit into close proximity the targets of their suppressive activity 
(Hoelzinger et al., 2010). Together these data indicated that under 
physiological conditions, a substantial portion of the effector Treg cell 
transcriptional program, but not the naive-like Treg cell transcriptional 
program, characterized by elevated expression of several potential Treg cell 
effector molecules, was maintained by continuous TCR signaling. 
 
IRF4 expression promotes Treg cell function and homeostasis 
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To begin to assess the importance of the TCR-dependent transcriptional 
program for continuous Treg cell function in vivo, we focused on IRF4 as a 
downstream target of the TCR signaling pathway in Treg cells. We confirmed 
that elevated IRF4 expression in Treg cells was restricted to CD44hi cells and 
was reduced to basal expression upon ablation of the TCR in both 
TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice (Figure 2.12A). 
Irf4FL/−Foxp3Cre-ERT2 mice, in which IRF4 is constitutively deleted in Treg cells, 
have been shown to develop severe autoimmunity dominated by type 2 helper 
T cell cytokines by 8 weeks of age (Zheng et al., 2009). Treg cells in Irf4−/− 
mice have been shown to have an almost exclusively naive-like phenotype 
(Cretney et al., 2011), and we similarly found that Treg cells in 
Irf4FL/FLFoxp3YFP-Cre mice were largely CD44loCD62Lhi, even in the context of 
severe inflammation (data not shown), which suggested impaired 
differentiation, survival and/or population expansion of effector Treg cells. 
 To determine whether fully differentiated Treg cells require IRF4 
expression downstream of TCR engagement for their in vivo suppressive 
function, we administered tamoxifen on days 0, 3, 7 and 10 to Irf4FL/FLFoxp3Cre-
ERT2 and Irf4WT/WTFoxp3Cre-ERT2 littermates (Klein et al., 2006). On day 13, we 
observed slightly but reproducibly lower IRF4 protein expression in CD44hi 
Treg lymph node cells from Irf4FL/FLFoxp3Cre-ERT2 mice than in cells from 
Irf4WT/WTFoxp3Cre-ERT2 mice (Figure 2.13A). We also saw higher GFP 
expression in the Treg cells, measured as a sum of fluorescence from the Irf4-
deletion GFP reporter (whose expression is switched on in the Irf4 locus by 
Cre-mediated deletion of the Irf4FL allele) and from the GFP-Cre-ERT2 fusion 
protein expressed concomitantly with Foxp3 (Figure 2.12B). Quantitative PCR 
analysis indicated ~50% lower abundance of Irf4 mRNA in Treg cells sorted  
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Figure 2.12. IRF4 expression in Treg cells is restricted to CD44hi cells, is 
TCR dependent and can be inducibly ablated in Irf4FL/FLFoxp3Cre-ERT2 
mice.  
(A) Histograms showing IRF4 protein levels in TCR+ Foxp3+ cells in 
TcraWT/WTFoxp3Cre-ERT2 (WT/WT; CD44loCD62Lhi in green and CD44hiCD62Llo 
in black) and in TcraFL/FLFoxp3Cre-ERT2 (FL/FL; CD44loCD62Lhi in orange and 
CD44hiCD62Llo in blue) mice (above), and in TCR- Foxp3+ cells in 
TcraFL/FLFoxp3Cre-ERT2 (FL/FL; CD44loCD62Lhi in green and CD44hiCD62Llo in 
red) mice (below). (B) Histograms demonstrating an increase in eGFP median 
fluorescence intensity (MFI) in eGFP+ cells following tamoxifen administration 
to Irf4FL/FLFoxp3Cre-ERT2 (red line) vs. Irf4WT/WTFoxp3Cre-ERT2 (black line) mice 
(left); quantitation of eGFP median fluorescence intensity of eGFP+ cells in 
Irf4WT/WTFoxp3Cre-ERT2 (white squares) and Irf4FL/FLFoxp3Cre-ERT2 (black 
squares) mice (right). Mice were administered tamoxifen on days 0, 3, 7 and 
10 and were analyzed on day 13. Data is representative of two experiments 
with three or more (A) or four or more (B) mice per group each. Pvalue in (B) 
was calculated using a two-tailed unpaired t-test. 
 
 





Figure 2.13. IRF4 expression contributes to optimal suppressive ability 
and homeostasis of Treg cells. 
(A) IRF4 expression in CD44hiCD62Llo (CD44hi) and CD44loCD62Lhi (CD62Lhi) 
CD4+Foxp3+ lymph node cells from Irf4WT/WTFoxp3Cre-ERT2 mice (Irf4WT/WT) and 
Irf4FL/FLFoxp3Cre-ERT2 mice (Irf4FL/FL) analyzed on day 13 following tamoxifen 
treatment on days 0, 3, 7 and 10 (left), quantitative PCR analysis of Irf4 mRNA 
in CD4+eGFP− and CD4+eGFP+ cells sorted from pooled spleens and lymph 
nodes of those mice. AU, arbitrary units. (B) IRF4 expression in colonic lamina 
propria CD4+Foxp3+cells in Irf4WT/WTFoxp3Cre-ERT2 and Irf4FL/FLFoxp3Cre-ERT2 
mice (left), and frequency of Foxp3+ cells among CD4+ cells in the large 
intestine lamina propria in TracWT/WTFoxp3Cre-ERT2 or Irf4WT/WTFoxp3Cre-ERT2 
mice (open circles) and TracFL/FLFoxp3Cre-ERT2 or Irf4FL/FLFoxp3Cre-ERT2 mice 
(filled circles) analyzed on day 13 following tamoxifen treatment on days 0, 3, 
7 and 10. Gray shaded curve (left), CD4+Foxp3− cells. (C,D) Number of cells 
and frequency of CD44hi or Ki67+ cells (C) or cytokine-producing cells (D) 
among CD4+Foxp3− T cells in the lymph nodes (C) and spleens (D) of 
TracWT/WTFoxp3Cre-ERT2 mice (open circles), Irf4WT/WTFoxp3Cre-ERT2 mice (open 
squares), TracFL/FLFoxp3Cre-ERT2 mice (filled circles) and Irf4FL/FLFoxp3Cre-ERT2 
mice (filled squares) analyzed on day 13 following tamoxifen treatment on 
days 0, 3, 7 and 10. Each symbol (B–D) represents an individual mouse; small 
horizontal lines indicate the mean. *P < 0.05, **P < 0.01 and ***P < 0.001 (two-
tailed unpaired t-test). Data are representative of two experiments with four or 
more mice per group in each (A,B, left) or are pooled from two experiments 
with four or more mice per group in each (A,B, right, C,D (error bars (A), s.d.). 
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from pooled spleens and lymph nodes of tamoxifen-treated Irf4FL/FLFoxp3Cre-
ERT2 mice than in those of Irf4WT/WTFoxp3Cre-ERT2 mice (Figure 2.13A). 
 We hypothesized that the suboptimal ~50% reduction in mRNA 
transcripts and the only slight reduction in IRF4 protein expression in the 
spleens and lymph nodes of Irf4FL/FLFoxp3Cre-ERT2 mice compared with that of 
Irf4WT/WTFoxp3Cre-ERT2 mice might have resulted from a competitive 
disadvantage of Treg cells that lack IRF4 protein. Such a disadvantage might 
lead to 'preferential' population expansion of the IRF4-sufficient Treg cells 
remaining in the Irf4FL/FLFoxp3Cre-ERT2 mice. This would be consistent with the 
published observation that the survival and expansion of strongly antigen-
stimulated CD8+ T cells is greatly impaired in the absence of IRF4 (Man et al., 
2013). 
 To determine whether IRF4 might similarly contribute to the 
maintenance of Treg cells that have been strongly activated, we assessed the 
colonic lamina propria, in which nearly all Treg cells were CD44hi and had 
probably recently experienced engagement of the TCR, given their robust IL-
10 production (data not shown). Indeed, we observed a lower frequency of 
colonic lamina propria Treg cells in Irf4FL/FLFoxp3Cre-ERT2 mice than in 
Irf4WT/WTFoxp3Cre-ERT2 mice (Figure 2.13B), similar to lower frequency of Treg 
cells in the colonic lamina propria of TracFL/FLFoxp3Cre-ERT2 mice than in 
TracWT/WTFoxp3Cre-ERT2 mice noted above. In contrast to spleen and lymph 
node Treg cells, and consistent with their lower frequency, colonic lamina 
propria Treg cells in Irf4FL/FLFoxp3Cre-ERT2 mice had much lower expression of 
IRF4 protein than did those in Irf4WT/WTFoxp3Cre-ERT2 mice (Figure 2.13B). We 
hypothesized that the reportedly low influx of circulating Treg cells into the 
colonic lamina propria at steady state may have precluded IRF4-sufficient cells 
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from becoming activated and repopulating to a wild-type frequency the Treg 
cell niche in this tissue (Smigiel et al., 2014). 
 Despite the only slightly lower IRF4 expression in Treg cells isolated 
from the spleens and lymph nodes of Irf4FL/FLFoxp3Cre-ERT2 mice than in their 
counterparts from Irf4WT/WTFoxp3Cre-ERT2 mice, we were able to detect a very 
mild, but statistically significant, increase in the frequency of CD44hi and Ki67+ 
lymph node Foxp3−CD4+ T cells, as well as increased production of IFN-γ, IL-
4 and IL-13 by splenic Foxp3−CD4+ T cells (Figure 2.13C,D). This suggested 
that IRF4 expression downstream of TCR signaling in Treg cells contributed to 
the suppressive function of Treg cells. An increase in the production of type 2 
helper T cell cytokines was consistent with the phenotype of mice with 
constitutive ablation of IRF4 in Treg cells, whereas the increased IFN-γ was 
probably a consequence of the substantial type 1 helper T cell bias in C56B/L6 
adult mice before induced Irf4 deletion (Zheng et al., 2009). 
 As a control, we confirmed that in the absence of tamoxifen treatment, 
the expression of CD44, Ki67, IFN-γ, IL-4 and IL-13 in CD4+Foxp3− T cells 
from Irf4FL/FLFoxp3Cre-ERT2 mice was indistinguishable from that in their 
counterparts from Irf4WT/WTFoxp3Cre-ERT2 mice, as was the frequency of Treg 
cells in the colonic lamina propria (data not shown). This suggested that the 
modest differences between Irf4FL/FLFoxp3Cre-ERT2 and Irf4WT/WTFoxp3Cre-ERT2 
mice that we observed upon tamoxifen treatment were not a consequence of 
the Irf4FL allele itself. Together these data indicated that even partial loss of 
IRF4 expression downstream of TCR engagement in Treg cells interfered with 
optimal suppressive function of these cells. 
 
Discussion 
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Despite major progress in understanding the molecular mechanisms of TCR 
engagement–driven differentiation of Treg cells, the role of the TCR in Treg 
cell function in vivo has remained unclear. Here we demonstrated that TCR 
signaling in differentiated Treg cells was dispensable for the maintenance of 
Foxp3 expression and for the expression of many characteristic markers of 
Treg cells. Although the bulk of the Treg cell–specific gene signature was also 
preserved in the absence of the TCR, suppressor function was critically 
dependent on the TCR. 
 Given that antigen-activated CD4+Foxp3− T cells in lymphoid organs 
are thought to produce IL-2 in a spatially restricted manner, we considered the 
possibility that Treg cells might analogously require their TCRs to correctly 
position themselves to gain preferential access to IL-2. This might elicit the 
suppressive function of Treg cells by stimulating IL-2R. However, our in vivo 
and in vitro data suggested that Treg cells acquired and probably effectively 
depleted IL-2 in a TCR-independent manner. Thus, these cells may instead 
rely predominantly on expression of the chemokine receptor CCR7 to ensure 
sufficient IL-2 exposure, as has been proposed (Smigiel et al., 2014). 
 Our observation that newly generated Treg cells in TracFL/WTFoxp3YFP-
Cre and TracFL/FLFoxp3YFP-Cre mice remained naive-like upon loss of the TCR 
and did not populate non-lymphoid tissues suggested that effector 
differentiation and population expansion were processes dependent on the 
TCR and probably dependent on antigens. This finding may help explain the 
observation that distinct TCR repertoires are displayed by Treg cell 
populations in different lymphoid organs and tissues in adult mice (Lathrop et 
al., 2011; Lathrop et al., 2008). Furthermore, inducible ablation of the TCR 
resulted in a far greater change in gene expression in the effector-like Treg cell 
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subset than in the naive-like subset. This suggested that continuous TCR 
signaling might be selectively driving the homeostasis and suppressor function 
of effector-like Treg cells. As inducible deletion of the TCR in differentiated 
Treg cells precipitated autoimmunity, our data may suggest that all or most of 
the suppressor function of Treg cells in vivo is mediated by the CD44hi 
effector-like Treg cell subset. 
 We found that partial inducible ablation of Irf4, expressed downstream 
of TCR engagement in CD44hi Treg cells, resulted in a very mild but 
reproducible activation of the immune system. This result suggested that IRF4 
expression was important for TCR-dependent Treg cell function; however, 
given the suboptimal deletion of Irf4 and very modest activation of the immune 
system, it remains to be determined to what extent and in what way TCR-
dependent induction of IRF4 in Treg cells contributes to their ability to 
suppress spontaneous autoimmunity. IRF4 may act mainly to control the 
maintenance of highly activated Treg cells, which was particularly evident in 
the colonic lamina propria and which, when altered, may affect the ability of 
the Treg cell pool to suppress. Alternatively, IRF4 may have a more direct role 
in promoting the suppressive activity of Treg cells, perhaps by driving the 
expression of certain Treg cell effector molecules. Although we observed 
decreased expression of the inducible costimulator ICOS on colonic Treg cells 
that lacked IRF4 (data not shown), the remaining IRF4-sufficient Treg cells in 
lymphoid organs of Irf4FL/FLFoxp3Cre-ERT2 mice preclude more rigorous 
identification of IRF4 targets. 
 However, we note that even though naive-like Treg cells did not 
express IRF4 and were overwhelmingly unaffected by TCR deletion on a 
transcriptional level, this did not necessarily indicate that these cells were 
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nonfunctional or were not experiencing TCR engagement. Indeed, several 
genes, including Egr1, Egr2 and Nr4a1, were downregulated in this Treg cell 
subset in the absence of the TCR. 
 Additional experiments are needed to elucidate the contributions of 
other individual TCR-dependent genes in Treg cells to the maintenance of 
immunotolerance in the steady state and to the restraint of immune responses 
directed against commensal microorganisms, food and environmental 
antigens and pathogens. In connection with this, we note that although IL-10 
production by Treg cells has been linked to the control of inflammatory 
responses at environmental interfaces such as the gut, lungs and skin, it has 
also been shown to be dispensable for Treg cell control over systemic 
autoimmunity (Rubtsov et al., 2008). Likewise, we found that whereas 
constitutive deletion of calcineurin B1 in Cnb1FL/FLFoxp3YFP-Cre mice (which 
eliminated calcineurin-dependent activation of NFAT in Treg cells) resulted in 
lethal early-onset autoimmunity, highly efficient inducible deletion in adult 
lymphoreplete Cnb1FL/FLFoxp3Cre-ERT2 mice had no detectable adverse effects 
on Treg cell function (data not shown). Together these findings suggest that 
engagement of the TCR on Treg cells may drive a focused transcriptional 
program, select aspects of which are required in a context-dependent manner 
for mediation of a broad range of Treg cell immunosuppressive functions. 
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Materials and Methods 
Mice 
Mice were bred and housed in the pathogen-free animal facility at Memorial 
Sloan-Kettering Cancer Center and were used in accordance with institutional 
guidelines. Unless otherwise noted, 8- to 10-week-old male and female sex-
matched mice were used for all experiments. Foxp3YFP-Cre, Foxp3eGFP-Cre-ERT2, 
Rosa26YFP, Foxp3DTR and Irf4FL mice have been described (Kim et al., 2007; 
Klein et al., 2006; Rubtsov et al., 2010; Rubtsov et al., 2008). M. Schmidt-
Supprian and K. Rajewsky provided TracFL mice. For tamoxifen administration, 
40 mg tamoxifen was dissolved in 100μl ethanol and subsequently in 900 μl 
olive oil (Sigma-Aldrich) and was sonicated four times for 30 s each in a 
Bioruptor Twin (Diagenode). Mice were given oral gavage of 200 μl tamoxifen 
emulsion per treatment. For injection of diphtheria toxin (DT), DT was 
dissolved in PBS and 200 μl of the appropriate dose was injected 
intraperitoneally into each mouse. For in vivo depletion of IL-2, mice were 
given tamoxifen by gavage on days 0 and 1 or on days 0, 3, 7 and 10 and 
were given intraperitoneal injection on days 4 and 8 of a 0.5mg 1:1 mixture of 
IL-2-neutralizing antibody (JES6-1A12 and S4B6-1; Bio X Cell) or IgG2a 
isotype-matched control antibody (Bio X Cell). For administration of IL-2–anti-
IL2 complexes, 1 μg recombinant mouse IL-2 (R&D Systems) was incubated 
for 10 min at room temperature with 5 μg JES6-1 (Bio X Cell) and was diluted 
to a volume of 200 μl in PBS immediately before intraperitoneal injection. Mice 
were given tamoxifen by gavage on days 0, 3, 7 and 10 and received IL-2–
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anti-IL-2 complexes or PBS on days 5, 7, 9 and 11. No animals were excluded 
from analyses. No statistical method was used to predetermine sample size. 
The experiments were not randomized. The investigators were not blinded to 
allocation during experiments or outcome assessment. 
 
Flow cytometry staining and cell isolation 
Cells were stained with LIVE/DEAD Fixable Yellow Dead Cell Stain (Molecular 
Probes) and the following antibodies: anti-CD4 (RM4-5), anti-CD8 (5H10), 
anti-TCRβ (H57-597); anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD25 
(PC61), anti-CD27 (A7R34), anti-Foxp3 (FJK-16s), anti-CTLA-4 (UC10-4B9), 
anti-CD39 (24-DMS1), anti-CD73 (TY/11.8), anti-Ki67 (SolA15), anti-CD103 
(2E7), anti-KLRG1 (2F1), anti-CCR6 (11A9), anti-CXCR3 (CXCR3-173), anti-
GITR (DTA-1), anti-IRF4 (3E4), anti-Egr2 (Erongr2), anti-CD11a (2D7), anti-
CD11a (M17/4), anti-IFNγ (XMG1.2), anti-IL4 (11B11), anti-IL13 
(eBio13A), anti-IL5 (BD Biosciences), anti-IL2 (JES6-5H4). For BrdU 
experiments, mice were given intraperitoneal injection of 1 mg BrdU (5-
bromodeoxyuridine) in 1 ml PBS and cells were stained with a BD Pharmingen 
BrdU Flow Kit. An LSR II flow cytometer (BD Bioscience) and FlowJo software 
(TreeStar) were used for flow cytometry. For cell isolation, CD4+ T cells were 
purified from pooled spleen and lymph node cell suspensions with magnetic 
Dynabeads (Invitrogen) and were further sorted with a FACSAria II cell sorter 
(BD Bioscience). Intracellular staining was performed with eBioscience 
Fixation Permeabilization buffers. For cytokine staining, lymph node and 
spleen cells were stimulated for 4–6 h at 37 °C, 5% CO2, with soluble anti-
CD3 (5 μg/ml; 2C11; Bio X Cell) and anti-CD28 (5 μg/ml; 37.51; Bio X Cell) in 
the presence of 1 μg/ml brefeldin A (Sigma). 
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In vitro proliferation assay 
DC populations were expanded in vivo by subcutaneous injection of cytokine 
Flt3L–secreting B16 melanoma cells into the left hind flank of B6 mice. Once 
tumors were visible, spleens from injected mice were dissociated for 20 min at 
37 °C, with shaking, in RPMI-1640 medium containing 1.67 units/ml Liberase 
TL (Roche) and 50 μg/ml DNase I (Roche). EDTA was added at a final 
concentration of 5 mM to stop digestion, and the resulting homogenate was 
processed for isolation of CD11c+ cells with a MACS mouse CD11c (N418) 
purification kit (Miltenyi Biotec). CD4+eGFP+ cells purified by flow cytometry 
from tamoxifen-treated TracFL/WTFoxp3Cre-ERT2 mice were labeled with 
CellTrace Violet according to the manufacturer's instructions (Molecular 
Probes) and were plated in triplicate in 96-well flat-bottomed plates (5 × 104 
cells per well) in medium containing 25 U/ml human recombinant IL-2 
(PeproTech) with or without equal numbers of DCs and with or without 100 
ng/ml LPS (Escherichia coli strain 0111:B4, Sigma-Aldrich). 
 
In vitro IL-2 stimulation and detection of phosphorylated STAT5 
TracFL/WTFoxp3Cre-ERT2 mice were treated with tamoxifen on days 0 and 1, and 
on day 9, CD4+T cells were purified from pooled spleen and lymph node cell 
suspensions with magnetic Dynabeads (Invitrogen). Cells were stained with 
anti-CD4 (RM4-5; Tonbo Biosciences) and anti-TCRβ (H57-597; Tonbo 
Biosciences), then were washed and plated in 96-well V-bottomed plates (1 × 
106 cells per well) in RPMI medium containing 10% FBS with or without 
increasing concentrations of IL-2, followed by incubation for 20 min at 37 °C. 
Cells were subsequently processed with BD Phosflow Lyse/Fix Buffer and 
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Perm Buffer III (BD Biosciences) and were stained with antibody to STAT5 
phosphorylated at Tyr694 (47/Stat5; BD Biosciences) according to the 
manufacturer's instructions. Treg cells were identified by eGFP expression. 
For ex vivo staining of phosphorylated STAT5, spleen and lymph nodes were 
dissociated at 4 °C in PBS (0.5% BSA) containing anti-CD4 and anti-TCRβ 
(both identified above), were stained for 10 min on ice and were washed twice 
before fixation. 
 
In vitro depletion of IL-2 
TracFL/WTFoxp3Cre-ERT2 mice were treated with tamoxifen on days 0 and 1, and 
on day 9, pooled spleens and lymph nodes were enriched for CD4+ cells and 
subsequently sorted to a purity of >99% into eGFP+TCRβ+, eGFP+TCRβ− and 
eGFP−TCRβ+ populations. Each population was divided among eight wells of 
a 96-well V-bottomed plate (2.5 × 105 cells/well) in 25 ul RPMI medium (10%) 
with or without increasing doses of recombinant human IL-2, followed by 
incubation for 2 h at 37 °C. Depletion of IL-2 from the medium was assessed 
with the BD Cytometric Bead Array and Human IL-2 Enhanced Sensitivity Flex 
Set according to the manufacturer's instructions (BD Biosciences). 
 
In vitro conjugation assay 
TracWT/WTFoxp3Cre-ERT2, TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 mice 
were treated with tamoxifen on days 0 and 1, and on day 9, CD4+ T cells were 
isolated from spleen and lymph nodes with the Dynabeads Untouched Mouse 
CD4 Cells negative selection kit (Invitrogen.) TCR+ Treg cells were sorted from 
TracWT/WTFoxp3Cre-ERT2 mice on the basis of eGFP expression alone. TCR− 
Treg cells were sorted from TracFL/WTFoxp3Cre-ERT2 and TracFL/FLFoxp3Cre-ERT2 
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mice as eGFP+TCRβ− cells. Treg cells were subsequently labeled with CFSE 
(carboxyfluorescein diacetate succinimidyl ester), and populations of DCs from 
mice with no deficiency or homozygous deficiency in MHC class II were 
expanded in vivo with Flt3L-secreting B16 melanoma cells and were labeled 
with CellTrace Violet. 1 × 104 Treg cells and 6 × 104 DCs were cultured 
together in a 96-well round-bottomed plate in RPMI medium 10% 
supplemented with 500 U/ml IL-2. Concanavalin A (C2010; Sigma) was used 
at a final concentration of 2.5 μg/ml. Following 10 h of culture at 37 °C, cells 
were gently resuspended before flow cytometry. 
 
Gene-expression analysis 
eGFP+ TCRβ+ and TCRβ− CD44hiCD62Llo cell populations (two replicates) and 
CD44loCD62Lhi cell populations (three replicates) were sorted from tamoxifen-
treated TracFL/WTFoxp3Cre-ERT2 mice (five or more mice per replicate) with a 
FACS Aria II flow cytometer. Complementary DNA (cDNA) libraries were 
amplified and hybridized to Affymetrix 430 2.0 chips. Arrays were normalized 
by the robust multiarray average method, and genes were considered to have 
a difference in expression if they had a q value of <0.01 after Benjamini-
Hochberg false-discovery rate correction. Differences in gene expression in 
Treg cells from Foxp3GFPKO mice and Foxp3+ mice has been described 
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CHAPTER 3 
SUPPRESSION OF LETHAL AUTOIMMUNITY BY REGULATORY T CELLS 




The regulatory T (Treg) cell T cell receptor (TCR) repertoire is highly diverse 
and skewed towards recognition of self-antigens.  In addition to an essential 
role of certain high affinity TCR-ligand interactions for Treg cell differentiation, 
TCR expression by Treg cells is continuously required for maintenance of 
immune tolerance and for a major part of their characteristic gene expression 
features; however, it remains unknown to what degree diverse TCR-mediated 
interactions between Treg cells and their cognate self-antigens are required 
for these processes.  Here, by experimentally switching the developmentally 
selected TCR repertoire to a single, previously characterized Treg cell TCR we 
demonstrate that to a significant extent, Treg cell function can be uncoupled 
from Treg cell specificity and diversity.  A monoclonal Treg cell pool exhibited 
essentially the full spectrum of TCR-dependent gene expression imparted by a 
diverse Treg cell TCR repertoire and was capable of suppressing lethal 
autoimmunity and TH2 and TH17, but not TH1, activation that occurs in the 
absence of TCR on Treg cells.  Although mice harboring Treg cells expressing 
predominantly this single TCR still displayed marked immune cell activation 
and tissue inflammation, our study suggests that Treg cells can exert 
																																																								
∗ Adapted from Levine, A.G., Hemmers, S., Schizas, M., Faire, M.B., Moltedo, B., Konapacki, 
K., Treuting, P.M., and Rudensky, A.Y. Suppression of lethal autoimmunity by regulatory T 
cells with a single TCR specificity. (submitted). 
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significant suppressor functions independently of specific interactions with 
developmentally selected cognate antigens. 
 
Introduction 
Increased thymic generation of regulatory T cells resulting from co-expression 
of transgene-encoded T cell receptors (TCR) and their cognate ligands 
provided the first experimental evidence that Treg cell differentiation is 
dependent upon self-antigen recognition in the thymus (Jordan et al., 2001).  
Transgene-driven expression of naturally occurring Treg cell-derived TCRs, 
however, has been found to yield few Treg cells with the majority of transgenic 
TCR-expressing cells differentiating into conventional CD4 T cells (Bautista et 
al., 2009; Leung et al., 2009).  This feature of Treg cell differentiation, ascribed 
to a profound intra-clonal competition amongst thymic Treg cell precursors, 
implies a stringent requirement for TCR diversity during Treg cell 
differentiation. Antigen presentation in the periphery is thought to mirror the 
thymus (Anderson et al., 2002), and analogously, limiting amounts of tissue-
specific self-antigens presented in draining lymph nodes likely maintain the 
activation status of small numbers of antigen specific Treg cells (Leventhal et 
al., 2016; Samy et al., 2005).  Nevertheless, it remains unknown whether 
diverse Treg cell specificities molded through recognition of a wide range of 
endogenous antigens during the differentiation process, are required for 
restraining a broad spectrum of autoimmune and inflammatory lesions that 
Treg cells normally control. 
Recently, we and others demonstrated that the Treg cell TCR controls 
expression of a large number of genes in activated Treg cells and is required 
for suppressor function such that TCR loss in Foxp3-expressing Treg cells 
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results in spontaneous immune activation and an early onset, highly 
aggressive fatal lymphoproliferative disease comparable to that observed in 
Foxp3-deficient mice lacking Treg cells (Levine et al., 2014; Vahl et al., 2014).  
However, these previous studies left open a question of which TCR-dependent 
gene expression features might be exhibited by Treg cells expressing just a 
few, or even a single TCR specificity, and whether these cells might afford any 
measure of protection against systemic fatal lymphoproliferative disease and 
tissue pathology.  Alternatively, there may be an absolute requirement for a 
diverse Treg TCR repertoire comprised of developmentally selected 
specificities for maintenance of the full spectrum of gene expression and 
suppressor function.   
In this regard, we recently reported that loss of TCRs within a lower 
affinity range for self-ligands in the developing Treg cell population in the 
absence of the intronic Foxp3 enhancer CNS3, had a mild effect on immune 
activation status without detectable clinical manifestations of autoimmunity 
suggesting that a reduced Treg cell repertoire with ‘holes’ was largely 
sufficient to support the bulk of Treg cell suppressor function (Feng et al., 
2015).  On the other hand, the severe autoimmunity apparent in mice with a 
combined deficiency in CNS3 and the autoimmune regulator (Aire) gene, 
which among other functions facilitates elimination of tissue-restricted antigen-
specific effector T cells and differentiation of Treg cells of corresponding 
specificities in the thymus, as well as other observations, suggest an important 
role for Treg cell TCR specificities in establishing tolerance early in life (Feng 
et al., 2015; Malchow et al., 2016; Samy et al., 2005; Yang et al., 2015).   
Efforts to directly address the role of TCR diversity and specificity for 
Treg cell function through the use of TCR transgenic mice have been impeded 
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by an inevitable concomitant severe skewing of the effector CD4 T cell 
repertoire.  Thus, while in some RAG-deficient TCR transgenic mice antigen-
specific Treg cells can keep in check effector T cells of the same specificity 
and prevent pathology (Killebrew et al., 2011; Lin et al., 2016), it is unknown 
whether a monoclonal Treg cell population can suppress a naturally diverse 
effector T cell pool.  Here, we addressed this question by exploring whether 
lethal autoimmunity exerted by a diverse effector T cell population upon the 
loss of Treg cell function can be restrained by Treg cells subjected to inducible 
skewing of their developmentally selected TCR repertoire to a single 
endogenous Treg cell-derived TCR.  Unexpectedly, in the presence of Treg 
cells expressing a single TCR we observed lasting, even if incomplete, 
protection from lethal disease resulting from complete ablation of the TCR in 
Treg cells, with diminished T cell activation and TH2 and TH17 cytokine 
production in select secondary lymphoid organs.  Moreover, expression of this 
single TCR also rescued essentially the entire gene signature imparted by a 
diverse Treg cell TCR repertoire.  These results indicate that the TCR-
dependent suppressor capacity of Treg cells to a considerable degree can be 
uncoupled from their developmentally established TCR-dependent recognition 
of diverse endogenous antigens.  
 
Results 
Monoclonal G113 TCR+ Treg cells suppress a diverse effector T cell pool 
To directly assess the role of Treg cell TCR diversity in driving suppressor 
function we took advantage of the previously characterized Treg cell-derived 
Vβ6+Vα2+ G113 TCR.  The G113 TCR, originally cloned out the CD4+CD25+ 
cell pool in TCli TCRβ-expressing Tcra+/- mice, is a typical Treg cell TCR in 
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that it induces strong signaling as well as proliferation and expansion when 
expressed in T cells in in vivo transfer experiments, but when expressed as a 
transgene on a RAG-deficient background generates a preponderance of 
conventional CD4 T cells and few Foxp3+ thymocytes (Hsieh et al., 2004; 
Hsieh et al., 2006; Moran et al., 2011).  Expression of the G113Tg on a RAG-
sufficient background results in highly efficient allelic exclusion of the 
endogenous Tcrb locus such that ~95% of Treg cells in G113Tg mice 
exclusively express the transgenic Vβ6+ TCRβ-chain.  Accordingly, as 
compared to Treg cells in non-G113Tg-expressing mice, Foxp3+ cells in 
G113Tg mice demonstrated minimal staining for endogenous TCRβ chains 
expressing Vβ5, Vβ8.1/2, Vβ11, Vβ12, and Vβ13 (Figure 3.1).  In contrast, 
less than half of Treg cells expressed the Vα2+ TCRα transgene (see Figure 
3.4A).  As a result, the majority of Treg cells in these mice are selected by 
TCRs composed of the transgenic Vβ6+ TCRb chain paired with an 
endogenous TCRα chain.  To enable replacement of diverse TCRs resulting 
from endogenous Tcra locus rearrangements with predominantly the single 
transgenic G113 TCR after Foxp3 induction, i.e. Treg cell lineage commitment, 
we generated G113TgFoxp3YFP-CreTcraFL/FL mice on a RAG-sufficient 
background (Figure 3.1 and Figure 3.2A).  In these mice, Foxp3 expression in 
developing Treg cells resulted in Cre recombinase-mediated ablation of the 
endogenous Tcra locus, leaving only the G113 Vα2+ TCRα chain to pair with 
transgenic TCRβ (Figure 3.1 and Figure 3.2A).  Thus, in G113TgFoxp3YFP-
CreTcraFL/FL mice, Treg cells were thymically generated in physiologic numbers 
via expression of endogenous TCRs that recognize endogenous ligands, while 
the peripheral Treg cell compartment was overwhelmingly of a single, 
monoclonal specificity.  Unique to this experimental set-up was the retention of  




Figure 3.1. Monoclonal expression of the G113 TCR in Treg cells.  
Mice of the indicated genotypes were analyzed at 2.5 weeks of age. A-B, 
Representative flow cytometry plots of TCR Vα and Vβ usage in CD4+Foxp3+ 
(A,B above) and CD4+Foxp3+TCRβ+ (A,B below) lymph node cells in the 
indicated mice.  Further gating of indicated cellular subsets is indicated by 
arrows.  Data are representative of several independent experiments. 





Figure 3.2. Monoclonal G113 TCR expressing Treg cells suppress 
autoimmune disease mediated by a polyclonal effector T cell population.  
Mice of the indicated genotypes were analyzed at 2.5 weeks of age. A, 
Representative flow cytometric analysis of lymph node CD4+Foxp3+ (above) 
and CD4+Foxp3- (below) cells in mice of the indicated genotypes. B, 
Representative mice of the indicated genotypes.  C, Survival curve for the 
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significant diversity in the effector T cell population with the majority of effector 
CD4+ T cells expressing endogenously rearranged TCRα chains (Figure 3.2A).  
 As we previously reported, all Foxp3YFP-CreTcraFL/FL mice suffered from 
an early onset lethal autoimmunity characterized by runting and scaly skin, 
and did not survive past four weeks of age (Figure 3.2B,C) (Levine et al., 
2014).  Unexpectedly, G113TgFoxp3YFP-CreTcraFL/FL mice were entirely 
indistinguishable from control mice bearing normal populations of Treg cells 
during the first weeks of life (Figure 3.2B).  Although by six weeks of age some 
G113TgFoxp3YFP-CreTcraFL/FL mice began to show signs of decreased weight 
gain and variable skin disease and ultimately succumbed to disease, a 
number of mice continued to show minimal signs of autoimmunity.  A striking 
50% of mice survived out to 4 months of age—the end point of the 
experiment—at which point all mice displayed evidence of significant 
autoimmunity (Figure 3.2C, data not shown). 
Consistent with overall increased survival, histological analysis of 
several tissues demonstrated a widespread but mild diminution of pathology in 
G113TgFoxp3YFP-CreTcraFL/FL compared to Foxp3YFP-CreTcraFL/FL mice (data not 
shown).  Critically, these effects did not appear to be the consequence of 
limited autoreactivity due to G113Tg expression on the effector T cell 
compartment, as G113TgFoxp3KO mice suffered from lethal autoimmunity 
largely indistinguishable from that of Foxp3KO mice lacking the TCR transgene 
(Figure 3.2B,C and data not shown) (Fontenot et al., 2003).  This result 
indicates that rescue of disease in G113TgFoxp3YFP-CreTcraFL/FL mice was due 
to effects of transgenic TCR expression specifically in the Treg cell 
compartment. 
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Indeed, the G113Tg in G113TgFoxp3YFP-CreTcraFL/FL mice fully rescued 
percentages and proliferation (as assess by Ki67 staining) of lymph node Treg 
cells, significantly rescued effector differentiation as assessed by CD44 and 
CD62L expression, and restored cell surface expression of the receptor IL1R2, 
among others (Figure 3.3A).  Lymph node effector CD4 T cell activation was 
correspondingly diminished, with decreased percentages of CD44hi and IL-4-, 
IL-13, and IL-17- but not IFNγ- or IL-2-producing cells (Figure 3.3B).  In the 
spleen, however, where rescue of Treg cell percentages was modest (Figure 
3.3C), effector T cell activation was not lessened (data not shown).  T cell 
activation and cytokine production was similar between Foxp3KO and 
G113TgFoxp3KO mice in both spleens and lymph nodes, further ruling out a 
dominant role for the G113Tg in decreasing T cell activation (data not shown).  
Thus, the degree of G113Tg-mediated Treg cell rescue correlated with the 
degree of suppression of effector T cell activation.  This further supported an 
essential role of G113 TCR-expressing Treg cells in down-modulating 
autoimmunity in G113TgFoxp3YFP-CreTcraFL/FL mice. 
 
Inducible replacement of the diverse TCR repertoire with the G113 TCR 
in mature Treg cells  
Given that Treg cells undergo TCR-dependent maturation in the 
periphery we sought to test whether mature Treg cells, which had seeded the 
spleen and tissues, subjected to inducible replacement of their TCRs with the 
G113 TCR remained functionally competent or would still be partially impaired 
in their ability to control immune activation, like Treg cells in 
Foxp3CreERT2TcraFL/FL mice (Levine et al., 2014).  Therefore, we generated 
G113TgFoxp3CreERT2TcraFL/FL mice to enable the switch of endogenous Treg 










Figure 3.3. The monoclonal G113 TCR rescues Treg cell activation and 
suppresses T cell activation in lymph nodes.  
Mice of the indicated genotypes were analyzed at 2.5 weeks of age. A, 
Percent Foxp3+ cells among CD4+ cells (top); and percent Ki-67+ (second from 
top), percent CD44hiCD62Llo (second from bottom) and IL1R2+ (bottom) cells 
among Foxp3+ cells in the lymph nodes of Foxp3YFP-CreTcraWT/FL (black 
circles), G113TgFoxp3YFP-CreTracWT/FL (gray circles), Foxp3YFP-CreTracFL/FL (red 
circles), and G113TgFoxp3YFP-CreTracFL/FL (blue circles) mice. B, CD4+Foxp3- 
T cell activation and cytokine production in lymph nodes of the indicated mice.  
C, The percent Foxp3+ of CD4+ T cells in spleens of the indicated mice.  Each 
circle represents an individual mouse; the horizontal bars represent mean 
value; p values were calculated using Student’s t test (***, **, and * denotes p 
values <0.001, 0.01, and 0.05, respectively; ns – not significant); the data 
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cell TCRs in mature Treg cells in adult mice for the G113 TCR in a tamoxifen-
inducible manner (Figure 3.4A).  Two weeks of tamoxifen administration to 
G113TgFoxp3CreERT2TracFL/FL mice resulted in clear increases in immune 
activation compared to control G113TgFoxp3CreERT2TracWT/WT mice (Figure 
3.4B-D).  This result indicates that the G113 TCR was not sufficient to impart 
full TCR-dependent Treg cell function in the periphery, even in a normally 
differentiated and localized Treg cell population. 
 We turned to an in vivo adoptive transfer approach to enable a more 
stringent assessment for suppressor activity of Treg cells whose diverse TCRs 
had been inducibly switched to the G113 TCR in comparison to Treg cells 
expressing diverse TCRs and Treg cells subjected to TCR ablation.  We 
FACS-sorted bulk Treg cells from Foxp3CreERT2TracWT/WT mice (control); Vβ6+ 
Treg cells from G113TgFoxp3CreERT2TracWT/WT mice; G113+ (Vβ6+Vα2+) Treg 
cells from G113TgFoxp3CreERT2TracFL/FL mice; and TCR-deficient (TCRβ-) Treg 
cells from Foxp3CreERT2TracFL/FL mice.  All groups of mice in these experiments 
were subjected to identical tamoxifen treatment.  Sorted cells were transferred 
together with pre-activated effector CD4+ T cells isolated from Treg cell-
depleted CD45.1+Foxp3DTR mice into T cell-deficient Tcrb/TcrdKO recipients 
analyzed four weeks after transfer (Figure 3.5A).  In agreement with the 
markedly diminished disease observed in G113TgFoxp3YFP-CreTracFL/F mice, 
co-transfer of G113+ Treg cells but not of TCR-deficient Treg cells substantially 
decreased parameters of immune activation including lymphadenopathy, CD4+ 
T cell numbers, and IFNγ production in lymph nodes but not in spleens of 
recipient mice (Figure 3.5B,C).  These results confirm the capacity of 
monoclonal G113+ Treg cells to exert remarkable, but incomplete suppressor  







Figure 3.4. Inducible replacement of the diverse TCR repertoire with the 
G113 TCR in mature Treg cells.  
G113TgFoxp3CreERT2TracWT/WT and G113TgFoxp3CreERT2TracFL/FL mice were 
treated with tamoxifen on days 0, 3, 7, and 10 and analyzed on day 13.  A, 
Representative flow cytometric analyses of lymph node CD4+Foxp3+ (above) 
and CD4+Foxp3- (below) cells in G113TgFoxp3CreERT2TracWT/WT (left) and 
G113TgFoxp3CreERT2TracWT/WT (right) mice. B, CD4+Foxp3- (right) and CD8+ 
(left) T cell activation in spleens (above) and lymph nodes (below) of 
G113TgFoxp3CreERT2TracWT/WT (white circles) and 
G113TgFoxp3CreERT2TracWT/WT (black circles) mice.  CD4+Foxp3- and CD8+ 
cells were further gated as either Vβ6Vα2+ (G113+) or Vβ6Vα2- (G113-) cells. 
C-D, T cell numbers in lymph nodes (C) and cytokine production in spleens 
(D) of mice of the indicated genotypes. 
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Figure 3.5.  Inducible replacement of the diverse TCR repertoire with the 
G113 TCR in mature Treg cells supports Treg cell function. 
A, Schematic of the experiment. Treg cells were sorted from the following mice 
on day 0 after tamoxifen administration on days -7 and -6:  bulk Treg cells 
from Foxp3CreERT2TcraWT/WT mice (black circles), Vβ6+ Treg cells from 
G113TgFoxp3CreERT2TcraWT/WT mice (gray circles), TCRβ- Treg cells from 
Foxp3CreERT2TcraFL/FL mice (red circles), and Vβ6Vα2+ Treg cells from 
G113TgFoxp3CreERT2TcraFL/FL mice (blue circles.) CD4+ effector T cells were 
isolated on day 0 from CD45.1+Foxp3DTR mice treated with diptheria toxin on 
days -5, -4, and -1.  On day 0, Treg cells and effector CD4+ T cells were 
transferred into Tcrb-/-Tcrd-/- mice subsequently maintained on weekly doses of 
diptheria toxin until analysis on day 28. B-C, Numbers of CD45.2+CD4+Foxp3+ 
Treg cells (top) and CD45.1+CD4+Foxp3- cells (middle) and percent IFNγ+ 
CD45.1+CD4+ cells in spleens (B) and skin-draining lymph nodes (C) in Tcrb-/-
Tcrd-/- mice transferred with CD45.1+CD4+ effector cells and either no Treg 
cells or Treg cell populations as described in (A).  Each circle represents an 
individual mouse; the horizontal bars represent mean value; p values were 
calculated using Student’s t test (***, **, and * denotes p values <0.001, 0.01, 
and 0.05, respectively; ns – not significant); the data shown represent the 
combined results of two independent experiments with at least four mice per 
group each.   
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activity in comparison to a Treg cell population expressing a diverse TCR 
repertoire.  These observations raised a question of whether the inability of 
Treg cells expressing a single TCR to fully control immune activation was due 
to its inability to impart a complete range of TCR-dependent gene expression 
or rather was due to limiting TCR ligand-driven activation restricted to specific 
local settings. 
 
Rescue of the Treg cell TCR-dependent gene signature by monoclonal 
G113 TCR expression 
Previously, we used microarray gene expression analysis to identify a set of 
TCR-dependent genes expressed in effector CD44hiCD62Llo Treg cells (155 
genes down- and 5 genes up-regulated with a 2-fold cut-off upon TCR  
ablation) and in CD44loCD62Lhi naïve Treg cells (16 genes down- and 1 gene 
up by 2-fold in the absence of TCR) (Levine et al., 2014).  In that study, 
analysis of TCR-sufficient and -deficient Treg cells sorted from healthy, 
tamoxifen-treated Foxp3CreERT2TracFL/WT mice, which due to allelic exclusion at 
the Tcra locus harbored both Treg cell subsets, showed that TCR dependent 
gene expression accounted for ~25% of the gene signature specific to 
activated Treg cells.  In order to address the major question of whether a 
single TCR specificity can enable a full or only partial spectrum of Treg cell 
gene expression, we performed RNA-seq analysis on effector and naïve TCR+ 
and TCR- Treg cells from Foxp3CreERT2TracFL/WT mice as well as effector and 
naïve TCR+ and TCR- Treg cells from immune activated Foxp3CreERT2TracFL/FL 
mice.  We also performed similar analysis for effector and naïve Treg cells 
isolated from tamoxifen-treated G113TgFoxp3CreERT2TracWT/WT and 
G113TgFoxp3CreERT2TracFL/FL mice. 
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 We defined an extensive set of potentially functionally important TCR-
dependent genes as all genes significantly under- or over-expressed in 
effector and naïve TCR-deficient Treg cells from Foxp3CreERT2TracFL/FL mice 
compared to TCR-sufficient Treg cells from healthy Foxp3CreERT2TracFL/WT 
mice.  We reasoned that the identified genes encompassed strictly TCR-
dependent transcripts, whose expression could not be rescued by TCR-
independent inputs resulting from the immune activation and inflammation 
observed in Foxp3CreERT2TracFL/FL mice.  Our RNA-seq analysis revealed a 
comprehensive set of 1,238 genes that were down- and 1,088 genes that were 
up-regulated in effector Treg cells in the absence of TCR; and 484 genes that 
were down- and 389 genes that were up-regulated in naïve Treg cells in the 
absence of TCR.  We next determined the extent to which changes in 
expression of these genes induced upon TCR ablation in effector and naïve 
Treg cells could be rescued upon expression of the G113 TCR transgene 
alone in G113TgFoxp3CreERT2TcraFL/FL mice compared to G113 TCR transgene 
expression in combination with diverse endogenously rearranged TCRs in 
G113TgFoxp3CreERT2TcraWT/WT mice. 
 Strikingly, the monoclonal G113 Treg cell-derived TCR was able to 
support expression of the vast majority of genes whose expression was found 
to be TCR-dependent in Treg cells expressing a diverse TCR repertoire 
(Figure 3.6A,B).  Of the 1,238 genes we identified as up-regulated in a TCR 
dependent manner in effector Treg cells, expression of 1008 (81%) was fully 
rescued by expression of the monoclonal G113 TCR in 











Figure 3.6.  Rescue of the polyclonal TCR-dependent gene signature in 
Treg cells upon expression of the monoclonal G113 TCR.  
A-B.  Foxp3CreERT2TracFL/WT, Foxp3CreERT2TracFL/FL, 
G113TgFoxp3CreERT2TracWT/WT, and G113TgFoxp3CreERT2TracFL/FL mice were 
treated with tamoxifen on days 0, 1, and 7 and on day 9 the following 
populations were sorted from the indicated mice: CD44hiCD62Llo and 
CD44loCD62Lhi TCRβ+ and TCRβ- Treg cells from Foxp3CreERT2TracFL/WT mice; 
CD44hiCD62Llo and CD44loCD62Lhi TCRβ+ and TCRβ- Treg cells from 
Foxp3CreERT2TracFL/FL mice; CD44hiCD62Llo and CD44loCD62Lhi Vβ6+ Treg 
cells from G113TgFoxp3CreERT2TracWT/WT mice; and CD44hiCD62Llo and 
CD44loCD62Lhi Vβ6Vα2+ Treg cells from G113TgFoxp3CreERT2TracFL/FL mice. 
A, Genes significantly up-regulated (left) or down-regulated (right) in 
CD44hiCD62Llo (above) and CD44loCD62Lhi (below) TCRβ+ Treg cells in 
Foxp3CreERT2TracWT/FL mice compared to TCRβ- Treg cells in 
Foxp3CreERT2TracFL/FL mice were analyze for significantly differential expression 
in the corresponding Treg cell subsets in G113TgFoxp3CreERT2TracWT/WT 
compared to G113TgFoxp3CreERT2TracFL/FL mice. Significantly up- (left, red) or 
down-regulated (right, blue) genes are shown as well as genes not 
significantly up- (black, left) or down-regulated (black, right). B, Cumulative 
distribution plots showing genes up- (left) and down-regulated (right) in 
CD44hiCD62Llo (CD44hi, black line) and CD44loCD62Lhi (CD62Lhi, dark green 
line) TCRβ+ Treg cells in Foxp3CreERT2TracWT/FL vs. TCRβ- Treg cells in 
Foxp3CreERT2TracFL/FL mice.  Distribution of the same genes is shown for 
CD44hiCD62Llo (CD44hi, gray line) and CD44loCD62Lhi (CD62Lhi, light green 
line) Vβ6+ Treg cells in G113TgFoxp3CreERT2TracWT/WT vs. Vβ6Vα2+ (G113+) 
Treg cells in G113TgFoxp3CreERT2TracFL/FL mice. Dotted gray and light green 
lines indicate where gray and light greens lines cross x = 0; numbers indicate 
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G113TgFoxp3CreERT2TcraWT/WT mice; these included genes coding for putative 
effectors and regulators of suppressor function Tigit, Fgl2, Cxcl10, Il10, Lag3, 
Icos, and Pdcd1; transcription factors Irf4, Myb, Nfatc1, Nr4a3, and Relb; and 
the chemokine receptor Ccr8.  Furthermore, for 154 of the remaining 230 
genes (67%) whose transcript levels were not fully rescued by monoclonal 
G113 TCR expression, the observed difference in their expression in 
monoclonal vs. polyclonal Treg cells from G113TgFoxp3CreERT2TcraFL/FL vs. 
G113TgFoxp3CreERT2TcraFL/FL mice, respectively, was less than that in TCR-
deficient vs. –sufficient Treg cells from Foxp3CreERT2TcraFL/FL vs. 
Foxp3CreERT2TcraFL/WT mice, respectively.  The latter group included typical 
TCR-dependent genes like Egr2, Egr3, Il1r2, Penk, Cd83, and Ebi3, all of 
whose difference in expression in non-G113Tg expressing TCR-deficient vs. –
sufficient Treg cells was two-fold or more greater than the difference in 
expression in monoclonal vs. polyclonal G113Tg-expressing Treg cells.  
Similarly, of the 1,088 genes up in effector Treg cells in the absence of TCR, 
944 (87%) were fully rescued.  A comparable—if not more profound—rescue 
of TCR-dependent gene expression was also observed for naïve Treg cells.  
We found that 426 of 484 (88%) genes up-regulated in a TCR-dependent 
manner were similarly expressed—or were actually overexpressed—in naïve 
monoclonal Treg cells in G113TgFoxp3CreERT2TcraFL/FL mice compared to Treg 
cells in G113TgFoxp3CreERT2TcraWT/WT mice expressing diverse endogenously 
rearranged TCRs.  The latter set included the genes Egr1, Egr2, Egr3, Cd5, 
Irf4, Myb, Nab2, and Nfatc1.  Likewise, of the 389 genes down-regulated in 
naïve Treg cells in a polyclonal TCR-dependent manner, 319 (82%) were fully 
rescued.  Together, these data demonstrate that at a population level, G113 
TCR expression rescues the vast majority, even if not all, of the TCR-
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dependent transcriptional signature in both effector and naïve Treg cell 
subsets. 
 
Selective activation of G113 TCR-expressing Treg cells in skin-draining 
lymph nodes   
The demonstration of widespread rather than limited rescue of TCR-
dependent gene expression in Treg cells by the monoclonal G113 TCR 
suggested that incomplete protection against autoimmune disease by these 
cells might be due to activation limited to a particular local setting rather than 
due to limited TCR-dependent gene expression induced by a given single 
TCR.  Thus, we next used flow cytometric analysis to examine expression of 
EGR2, as a representative TCR-dependent gene that was somewhat but not 
fully rescued by the monoclonal G113 TCR.  In lymph node effector Treg cells, 
we observed that compared to polyclonal Treg cells a decreased portion of 
monoclonal G113+ Treg cells were positive for EGR2 (69±0.78% vs 52±5.7%) 
consistent with restricted engagements with limiting amounts of antigen 
precluding full activation of the monoclonal G113+ Treg cell pool.  TCR-
deficient Treg cells used as a control showed negligible EGR2 expression 
(5.0±0.20%.)  Conversely, we noted that EGR2 was expressed at higher levels 
in naïve monoclonal G113+ Treg cells in the lymph nodes of 
G113TgFoxp3CreERT2TcraFL/FL mice than in naïve polyclonal Treg cells from 
G113TgFoxp3CreERT2TcraWT/WT mice (Figure 3.7A).  Even Vβ6+Vα2+ G113+ 
Treg cells in G113TgFoxp3CreERT2TcraWT/WT mice expressed more EGR2 than 
non-G113 Vβ6+Vα2- Treg cells in the same mice (Figure 3.7A).  Notably, this 
was not the case in the splenic Treg cell subset (Figure 3.7A) nor was this true 
for Treg cells found in intestine-draining mesenteric or lung-draining  













Figure 3.7. Selective activation of G113 TCR-expressing Treg cells in 
skin-draining lymph nodes.  
A, Representative flow cytometric analyses of EGR2 expression in naïve 
TCRβ+ and TCRβ- Treg cells in skin-draining lymph nodes and spleen in 
tamoxifen-treated Foxp3CreERT2TracWT/WT and Foxp3CreERT2TracFL/FL mice, 
respectively (left); and EGR2 expression in naïve Vβ6+Vα2- (G113-, black 
gates and histograms) and Vβ6+Vα2+ (G113+, red gates and histograms) Treg 
cells in tamoxifen-treated G113TgFoxp3CreERT2TracWT/WT and 
G113TgFoxp3CreERT2TracFL/FL mice (right).  B, Flow cytometric analyses of 
Treg cells in lymph nodes of female Foxp3CreERT2/YFP-CreTracFL/FL (left) and 
G113TgFoxp3CreERT2/YFP-CreTracFL/FL (right) mice, gated on CD4+Foxp3+ cells.  
The percentages YFP-Cre+ and YFP-Cre- (eGFP+) cells are indicated. C, Vα2 
and Vβ6 expression in eGFP-CreERT2+ (eGFP+) and YFP-Cre+ CD4+Foxp3+ 
cell subsets as shown in (B, right) in lymph nodes of G113TgFoxp3CreERT2/YFP-
CreTracFL/FL mice. D, Representative flow cytometric analyses (left) of 
CD4+Foxp3+ cells isolated from tissues of G113TgFoxp3CreERT2/YFP-CreTracFL/FL 
mice.  Quantification of YFP-Cre+ cells within the total Foxp3+ cell population is 
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mediastinal lymph nodes (data not shown).  Thus, G113 TCR activation was 
evident only in the skin-draining cervical, axial, brachial, and inguinal lymph 
nodes.  TCR-dependent IRF4 expression assessed at a single cell level 
showed a pattern similar to that of ERG2 (data not shown).  Intriguingly, these 
data suggested that the G113 TCR might recognize (with an affinity 
significantly higher than the average naïve Treg cell TCR) antigen 
predominantly expressed in the skin and consequently presented to naive 
G113+ Treg cells trafficking through skin-draining lymph nodes. 
 In order to further investigate this possibility, we generated female 
G113TgFoxp3CreERT2/YFP-CreTracFL/FL mice in which, due to X-inactivation, half 
of the Treg cells express eGFP-CreERT2 and half express YFP-Cre (Figure 
3.7B).  We reasoned that in this setting—in the absence of tamoxifen 
treatment—where monoclonal G113+ YFP-Cre+ Treg cells compete with 
polyclonal eGFP-CreERT2+ Treg cells (Figure 3.7C), the tissue expressing 
highest amounts of antigen recognized by the G113 TCR would enable 
accumulation and contain the relatively highest proportion of YFP-Cre+ G113+ 
Treg cells.  Indicative of G113 TCR recognition of a primarily skin-derived 
antigen, we observed most prominent accumulation of YFP-Cre+ cells as a 
percentage of total Foxp3+ cells in skin compared to other tissues (Figure 
3.7D).  These data suggest that a single Treg cell TCR with an apparent 
specificity for a yet to be identified antigen, apparently expressed in a tissue-
restricted manner, is sufficient to elicit the vast majority of the polyclonal TCR-
dependent gene expression signature and life-sparing immunosuppressive 
function in Treg cells. 
 
Discussion 
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Our studies provide a nuanced answer to an outstanding question in the field 
of Treg cell biology, namely, the requirement for a diverse TCR repertoire 
displayed by Treg cells for their suppressor function in vivo.  Although a 
diverse repertoire in mature Treg cells was required for their ability to control 
TH1 immune responses and fully restrain tissue inflammation, a single TCR, 
expressed by Treg cells, unexpectedly endowed them with the capacity to 
suppress lymphadenopathy and TH2 responses.  It should be noted that when 
transferred into T cell-deficient hosts, monoclonal Treg cells did suppress TH1 
responses in the lymph nodes; however, in this setting TH2 cytokines are 
barely detectable and, accordingly, this experimental set-up may not provide a 
suitable model for examining specific control of the Th2 responses. 
 Treg cells expressing the G113 TCR were able to markedly extend the 
lifespan of mice by restraining fatal early onset autoimmune disease resulting 
from congenital or induced Treg cell deficiency or from ablation of TCR 
expression in Treg cells (Fontenot et al., 2003; Kim et al., 2007; Levine et al., 
2014).  Consistent with functional studies, expression of this single monoclonal 
Treg cell-derived TCR was able to support the vast majority of gene 
expression features imparted by a diverse Treg TCR repertoire.  These 
findings suggested that a diverse Treg TCR mosaic was required for activation 
of Treg cells in specific “geographical” locations, rather than for enabling 
expression of distinct gene subsets induced in an individual TCR specificity-
dependent manner involved either directly or indirectly in elaboration of 
suppressor function.  This notion was supported by the observed preferential 
stimulation of Treg cells expressing the monoclonal G113 TCR in skin-draining 
lymph nodes, where they also seem to preferentially exert their suppressor 
function.  An additional and non-mutually exclusive possibility was that 
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suppression of immune responses in the lymph nodes and, in particular, of 
TH2 responses has less stringent requirements for diverse TCR-dependent 
interactions between Treg cells and their developmentally established cognate 
antigens as opposed to TH1 responses, whose suppression by Treg cells may 
more strictly require diverse and specific Treg cell TCR-ligand interactions.  In 
support of the latter possibility, we found that, similar to inducible G113 TCR 
expression in mature Treg cells, replacement of a diverse TCR repertoire 
recognizing developmentally selected ligands for a diverse, but biologically 
irrelevant TCR repertoire with randomly generated specificities resulted in 
protection against lymphadenopathy and TH2, but not TH1 responses.  The 
latter Treg TCR repertoire switch was accomplished by inducible Cre-mediated 
expression of the invariant Vα14-Jα18 NKT cell TCRα-chain in place of 
concomitantly ablated endogenously rearranged diverse TCRα-chains 
specifically in mature Treg cells in vivo (Vahl et al., 2013) (data not shown).  
TH1 vs. TH2 lineage commitment has been linked to TCR signal strength that 
can be modulated through co-stimulation (van Panhuys et al., 2014).  It is 
possible that a decrease in antigen presenting cell activation in lymph nodes 
imparted by a largely monoclonal G113+ Treg cell population or 
aforementioned Treg cells with diverse, but biologically irrelevant TCR 
specificities, underlies the observed differential suppression of TH1 and TH2 
responses, although precisely how this may occur is unclear.  In any case, our 
data indicate that once Treg cells have engaged their TCRs (no matter the 
antigenic specificity) they are able to exert a tolerogenic influence on their 
surroundings.  The observed partial rescue of immune activation and 
autoimmune disease in mice harboring a largely monoclonal population of 
G113+ Treg cells gives a measure of both the power and limitations of such 
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Materials and Methods 
Mice 
Foxp3YFP-Cre (Rubtsov et al., 2008), Foxp3eGFP-CreERT2 (Rubtsov et al., 2010), 
TcraFL (Polic et al., 2001), Foxp3KO (Fontenot et al., 2003), G113Tg (Bautista 
et al., 2009), Foxp3DTReGFP (Kim et al., 2007), and TracFL/Vα14i-StopF (Vahl et al., 
2013) mice have been previously described.  CD45.1 and Tcrb-/-Tcrd-/- mice 
were purchased from Jackson Laboratories.  Generation and treatments of 
mice were performed under protocol 08-10-023 approved by the Sloan 
Kettering Institute (SKI) Institutional Animal Care and Use Committee. All 
mouse strains were maintained in the SKI animal facility in specific pathogen 
free (SPF) conditions in accordance with institutional guidelines. 
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For tamoxifen administration, 40 mg tamoxifen dissolved in 100 μl ethanol 
and subsequently in 900 mL olive oil (Sigma-Aldrich) were sonicated 4 × 30 
seconds in a Bioruptor Twin (Diagenode). Mice were orally gavaged with 
200μl tamoxifen emulsion per treatment. For diphtheria toxin (DT) injections, 
DT (Sigma-Aldrich) was dissolved in PBS and 200 μl of indicated doses were 
injected i.p per mouse. 
 
Isolation of cells 
Spleens and lymph nodes were dissociated using ground glass slides and 
filtered.  Red blood cells in spleens were lysed before analysis.  To isolate 
lymphocytes from tissues, mice were euthanized and immediately perfused 
with 20 mL PBS.  Small and large intestines were removed, flushed with PBS, 
Peyer’s patches were removed, and residual fat and connective tissue was 
removed.  Intestines were opened lengthwise and cut into 0.5 cm-long pieces 
that were further washed by vortexing in PBS.  Samples were incubated in 
PBS supplemented with 5% fetal calf serum, 1% L-glutamine, 1% penicillin-
streptomycin, 10 mM HEPES, 1 mM dithiothreitol, and 1 mM EDTA for 15 
minutes to dissociate intraepithelial lymphocytes, which were discarded.  
Samples were washed and incubated in digest solution (RPMI supplemented 
with 5% fetal calf serum, 1% L-glutamine, 1% penicillin-streptomycin, 10 mM 
HEPES, 1 mg/mL collagenase, and 1 U/mL DNase I) for 10 minutes.  Cells 
were collected through a 100-μm strainer, and the residual samples were 
incubated in digest solution again for 10 minutes before filtering through 100-
μm strainers and combining with previously collected cells.  Cells were 
resuspended in 35% Percoll to eliminate debis before resuspension in staining 
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buffer.  To isolate lymphocytes from livers and lungs, tissues were physically 
dissociated using scissors and incubated for 50-60 minutes in digest solution 
before being filtered through 100-μm strainers.  Lungs samples were 
resuspended in 35% Percoll to eliminate debris before resuspension in 
staining buffer.  Lymphocytes from liver samples were resuspended in 44% 
Percoll, underlaid with 67% Percoll, and spun at 1000xg for 7.5 minutes at 
room temperature.  Cells were collected from the interface of the Percoll layers 
and washed before resuspension in staining buffer. 
 
Cell transfer experiments 
For cell transfer experiments, pooled spleens and lymph nodes were enriched 
for CD4 T cells using the Dynabeads CD4 Positive Isolation Kit.  Cells were 
FACS-sorted on an Aria II cell sorter (BD Bioscience), washed 3 times in PBS, 
resuspended in 200 µL PBS, and transferred into recipients via retro-orbital 
injection.    
 
Flow cytometric analysis 
Cells were stained with LIVE/DEAD Fixable Yellow Dead Cell Stain (Molecular 
Probes) and the following antibodies purchased from eBioscience, BioLegend, 
BD Biosciences, Tonbo, or obtained from the NIH tetramer core facility: anti-
CD4 (RM4-5), anti-CD8a (5H10), anti-TCRβ (H57-597), anti-Vβ6 (RR4-7), 
anti-Vα2 (B20.1), EGR2 (erongr2), IRF4 (E3 4), IL1R2 (4E2), PBS-57-loaded 
mCD1d tetramer, anti-CD44 (IM7), anti-CD62L (MEL-14), anti-CD25 (PC61), 
anti-Foxp3 (FJK-16s), anti- IFNγ (XMG1.2), anti-IL-4 (11B11), anti-IL-13 
(eBio13A), anti-IL-17A (17B7), and anti-IL-2 (JES6-5H4).  Flow cytometric 
analysis was performed using an LSRII flow cytometer (BD Bioscience) and 
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FlowJo software (Tree Star). Intracellular staining was performed using 
eBioscience Fixation Permeabilization buffers. For cytokine staining 
lymphocytes were stimulated with soluble anti-CD3 clone 2C11 (5μg/ml) and 
anti-CD28 clone 37.51 (5μg/ml) in the presence of 1μg/mL brefeldin A for 5 
hours at 37°C, 5% CO2. 
 
RNA-seq analysis 
Foxp3CreERT2TracFL/WT, Foxp3CreERT2TracFL/FL, G113Tg;Foxp3CreERT2TracWT/WT, 
and G113TgFoxp3CreERT2TracFL/FL mice were treated with tamoxifen on days 0, 
1, and 7 and on day 9—following CD4 T cell enrichment using the Dynabeads 
CD4 Positive Isolation Kit—the following populations were sorted from the 
indicated mice and resuspended in Trizol: CD44hiCD62Llo and CD44loCD62Lhi 
TCRβ+ and TCRβ- Treg cells from Foxp3CreERT2TracFL/WT mice; CD44hiCD62Llo 
and CD44loCD62Lhi TCRβ+ and TCRβ- Treg cells from Foxp3CreERT2TracFL/FL 
mice; CD44hiCD62Llo and CD44loCD62Lhi Vβ6+ Treg cells from 
G113TgFoxp3CreERT2TracWT/WT mice; and CD44hiCD62Llo and CD44loCD62Lhi 
Vβ6+Vα2+ Treg cells from Foxp3CreERT2TracFL/FL mice.  Three replicates of 
each cell subset were generated.  RNA-sequencing reads were aligned to the 
reference mouse genome GRCm38 using the Burrows-Wheeler Aligner (BWA) 
(Li and Durbin, 2010) and local realignment was performed using the Genome 
Analysis Toolkit (GATK) (McKenna et al., 2010). For each sample, raw count 
of reads per gene was measured using R, and DESeq2 R package (Love et 
al., 2014) was used to perform differential gene expression among different 
conditions. A cutoff of 0.05 was set on the obtained p values (that were 
adjusted using Benjamini-Hochberg multiple testing correction) to get the 
significant genes of each comparison. 




All statistical analyses (excluding RNA-seq analyses, described above) were 
performed using GraphPad Prism 6 software.  Differences between individual 
groups were analyzed for statistical significance using the unpaired or paired 
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CHAPTER 4 
STABILITY AND FUNCTION OF REGULATORY T CELLS EXPRESSING 
THE TRANSCRIPTION FACTOR T-BET∗ 
 
Abstract 
Regulatory T (Treg) cells comprise a distinct anti-inflammatory cell lineage 
specified by the transcription factor Foxp3.  Paradoxically, upon activation 
Treg cells can express transcription factors specifying pro-inflammatory 
effector T cell lineages.  Whether expression of these factors may indicate 
stability of Treg cell effector states and reflect essential Treg cell 
heterogeneity, or readily reversible activation states is unknown.  Using 
genetic fate mapping we demonstrate that in some Treg cells expression of 
the TH1-associated transcription factor T-bet, gradually acquired upon Treg 
cell effector differentiation in the periphery, induced at steady state and 
following infection is highly stable even under non-permissive conditions.  
Selective “loss-of-function” or elimination of T-bet-expressing Treg cells—but 
not of T-bet itself —resulted in a severe and selective TH1-type autoimmunity, 
demonstrating a major immunosuppressive function that cannot be 
compensated for by the remaining T-bet-non-expressing Treg cell pool.  These 




∗ Adapted from Levine, A.G., Hemmers, H., Moltedo, B., Niec, R.E., Schizas, M., Hoyos, 
B.E., Putintseva, E.V., Chaudhry, A., Dikiy, S., Chudakov, D.M., Treuting, P.M., and 
Rudensky, A.Y. Stability and function of regulatory T cells expressing the transcription factor 
T-bet. (submitted). 
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Introduction 
Protective immune responses against different types of pathogens are 
facilitated by clonal expansion and differentiation of naïve CD4 T cells into 
functionally distinct subsets of pathogen-specific effector CD4+ T cells, each 
endowed with specific effector functions tailored to the particular type of 
pathogens whose antigens they recognize (Zhu et al., 2010).  Acquisition of a 
given effector cell fate, for example, differentiation into the IFNγ-producing TH1 
lineage upon viral or bacterial infection is associated with repression of an 
alternative cell fate—differentiation into IL-4- or IL-13-producing TH2 effector 
cells.  The latter, while capable of exerting effective defenses against helminth 
infection, are ineffective—or even detrimental—for protection against bacterial 
infection.   
 This process of effector differentiation and acquisition of effector 
mechanisms is elicited through activation of particular STAT transcription 
factor family members and their corresponding key downstream transcription 
factors, T-bet, RORγt, and GATA3, to specify the appropriate response type in 
effector CD4 T cells (Zhu et al., 2010).  Similar effector mechanisms, however, 
also underlie misguided responses against “self”, commensal microbiota, and 
dietary antigens associated with a variety of autoimmune and inflammatory 
diseases.   
 Regulatory T (Treg) cells express their own X-chromosome encoded 
lineage defining transcription factor Foxp3, which is continuously required for 
their suppressor function (Fontenot et al., 2003; Gavin et al., 2007; Hori et al., 
2003; Khattri et al., 2003; Williams and Rudensky, 2007).  Fate mapping 
studies have indicated that Treg cells are a distinct cell lineage characterized 
by heritable maintenance of Foxp3 gene expression enforced by a dedicated 
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genetic mechanism (Feng et al., 2014; Rubtsov et al., 2010).  However, some 
activated Treg cells express, in addition to Foxp3, the aforementioned effector 
CD4 T cell signature transcription factors, which have been suggested to 
endow Treg cells with enhanced ability to suppress effector responses (Koch 
et al., 2009; Lee et al., 2015; Ohnmacht et al., 2015; Rudra et al., 2012; Sefik 
et al., 2015; Wohlfert et al., 2011).   
 Despite these observations, it remains unclear whether expression of 
these factors in Treg cells—akin to helper T cells—is indicative of 
heterogeneity of potentially functionally discrete and/or stable differentiation 
states.  It has been proposed that effector transcription factor expression in 
Treg cells may be readily reversible, in which case these cells would represent 
inducible and transitory states within a largely homogeneous activated Treg 
cell population (Liston and Gray, 2014; Tian et al., 2012).  Alternatively, 
heterogeneity of activated Treg cells—stemming from distinct effector Treg cell 
differentiation states—may be an essential feature of Treg cell-mediated 
tolerance, with subpopulations of Treg cells serving particular roles in 
controlling distinct types of inflammatory responses. 
In this regard, several recent studies of the functional implications of 
expression of T-bet—the TH1-specifiying transcription factor—in Treg cells 
failed to reveal defects in tolerance at steady state or in a variety of challenge 
conditions in mice subjected to Treg cell-specific ablation of this factor 
(Colbeck et al., 2015; McPherson et al., 2015; Yu et al., 2015).  Furthermore, 
fate mapping experiments utilizing a Tbx21 (T-bet) BAC transgene-encoded 
Cre recombinase fused to an estrogen receptor ligand binding domain 
(CreERT2), in combination with a recombination reporter, suggested that 
expression of T-bet in Treg cells was transient and reversible (Yu et al., 2015).  
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This study suggested that, in Treg cells, T-bet expression was functionally 
interchangeable with GATA3, thus implying a marked degree of Treg cell 
plasticity. 
Here, we explored the question of Treg cell heterogeneity and its 
functional implications through generation of a novel Tbx21 fate-mapping 
knock-in allele.  We found that T-bet expression was independently induced in 
Treg cells at steady state and upon bacterial or viral infection promoting TH1 
immune responses.  T-bet expression in Treg cells with high amounts of T-bet 
(following a gradual up-regulation of T-bet during peripheral effector 
differentiation) was remarkably stable at both steady state and under TH2-
polarizing conditions induced upon helminthic infection.  T-bet expression 
induced in Treg cells by bacterial infection was also highly stable, persisting in 
cells following resolution of the primary response as well as during the recall 
response to secondary challenge.  Selective loss-of-function or elimination of 
T-bet-expressing Treg cells resulted in a severe spontaneous TH1-type 
autoimmune inflammation that could not be compensated for by the remaining 
T-bet-non-expressing Treg cell pool.  In contrast, loss of T-bet itself in Treg 
cells did not impair their ability to prevent disease.  These results suggest a 
particular function differentiated Treg cells expressing T-bet in preventing 
autoimmunity and suggest an essential role of Treg cell heterogeneity in 
immunological tolerance.   
 
Results 
Stability of T-bet expression in peripheral Treg cells 
In order to determine whether T-bet expression was stable or rather was 
reversible, we generated a Tbx21tdTomato-T2A-CreERT2 knock-in allele containing 
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sequence encoding tandem dimer (td) Tomato red fluorescent protein (RFP) 
and CreERT2 separated by a self-cleaving 2A peptide sequence (Figure 
4.1A).  For fate mapping studies we combined this new allele with the 
Foxp3Thy1.1 reporter and the R26Y recombination reporter allele harboring a  
“floxed” stop cassette followed by YFP coding sequence inserted into the 
ubiquitously expressed Rosa26 locus (Liston et al., 2008; Srinivas et al., 
2001). The resulting mice, bred to homozygosity at each locus, (referred to 
hereafter as Tbx21RFP-CreERT2 mice) showed a dynamic range of RFP 
expression and CreERT2 activity corresponding to T-bet protein levels in 
major lymphocyte subsets including NK and NKT cells, Treg cells, and effector 
CD4 and CD8 T cells (Fig 4.1B and Figure 4.2A).   
 To assess stability of T-bet expression in Treg cells under physiologic 
conditions, Tbx21RFP-CreERT2 mice were treated with tamoxifen twice at 2 month 
of age and analyzed three weeks, three months, and seven months later for 
RFP and YFP expression (Figure 4.1C and Figure 4.2C).  RFP+ Treg cells 
were present in lymphoid organs and all non-lymphoid tissues examined, most 
prominently the colon; the latter Treg cell population exhibited prevalent co-
expression of T-bet and RORγt—as previously reported—but not T-bet and 
GATA3, confirmed by flow cytometric analysis of Tbx21RFP-CreERT2RorcGFP/WT 
mice (Figure 4.1D,F and Figure 4.21D-G) (Eberl et al., 2004; Sefik et al., 
2015).  In all tissues, excepting the colon, RFP+ cells comprised between 30-
40% of CD44hiCD62Llo effector Treg cells, which contain the bulk of RFP+ cells 
(Figure 4.2H); in the colon they comprised 67% (Figure 4.2I).  Over time, the 
percent RFP+ cells among Thy1.1+ Treg cells increased significantly in spleen 
and lymph nodes (Figure 4.1F); this was due both to increased percentages of  
 
 


















Figure 4.1. Stable T-bet expression in a subset of peripheral Treg cells.  
A, Targeting strategy for generation of the Tbx21RFP-CreERT2 allele. B, RFP 
expression (left) and percent YFP+ cells (right) in indicated splenic cell 
populations of Tbx21RFP-CreERT2 mice 3 weeks following tamoxifen (tx) gavage 
on days -2 and 0.  Numbers on graph (right) indicate the percent YFP+ cells of 
each cell type.  C, Schematic of the regimen of tx administration to Tbx21RFP-
CreERT2 mice in experiments shown in (D-G). D, Flow cytometric analysis of 
TCRβ+ CD4+ cells, which were negative for a-galalctosyl ceramide analogue 
(PBS-57)- loaded CD1d tetramer staining, 3 weeks post tx gavage. E, Flow 
cytometric analysis of splenic Thy1.1+ (above) and Thy1.1- (below) cells 3 
weeks, 3 months, and 7 months post tx gavage; cells were gated on TCRβ+ 
PBS-57-CD1d tetramer- CD4+ cells. F, (Above) percent RFP+ (left axis, 
squares) and YFP+ (right axis, circles) cells of Thy1.1+ cells, and (below) 
percent RFP+ of Thy1.1+YFP+ cells 3 weeks (white squares), 3 months (gray 
squares), and 7 months (black squares) post tx gavage. G, same as in (F) for 
Thy1.1- cells. The data shown represent the combined results of 2 






























Figure 4.2. Analysis of T-bet+ Treg cells in Tbx21RFP-CreERT2 reporter mice.  
A, Endogenous T-bet protein levels in select immune cell types in Tbx21RFP-
CreERT2  mice. B, Tbx21RFP-CreERT2  mice were orally gavaged with tamoxifen on 
days -2 and 0.  Three weeks later, splenic cells were fixed and stained for T-
bet.  Gray shaded histograms show T-bet expression in the bulk indicated cell 
types; open histograms show T-bet expression in the YFP+ cells of each 
indicated cell type. C, Fate mapping schematic for experiments described in 
Figure 1. D, Representative flow cytometric analysis of T-bet expression in 
GATA3+ (blue gate, left, and histogram, right) and RORγt+ (black gate, left, 
and histogram, right) CD4+Foxp3+ cells isolated from the large intestine 
laminia propria. E,F, Quantification of percent RFP+ cells among GFP+ TCRβ+ 
PBS-57 CD1d tetramer- CD4+ Thy1.1+ (E) and Thy1.1- (F) cells in Tbx21RFP-
CreERT2RorcGFP/WT mice. G, Representative flow cytometric analysis of 
CD4+Thy1.1+ (above) and Thy1.1- (below) cells as quantified in (E-F).  H, 
Representative flow cytometry analysis of splenic CD4+Thy1.1+ cells.  I, 
Percent CD44hiCD62Llo among Thy1.1+ cells (above) and the percent RFP+ 
among CD44hiCD62Llo Thy1.1+ cells (below) in Tbx21RFP-CreERT2 three weeks 
(white squares), three months (gray squares), and seven months (black 
squares) post tx treatment.  The data is representative of 2 independent 
experiments with at least 5 mice each (A-B,H); or represent the combined 
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RFP+ cells among CD44hiCD62Llo effectors (Figure 4.2I).  In contrast to a 
previous report, three weeks post tamoxifen administration we found the vast 
majority of both YFP-labeled Treg cells and effector CD4+ T cells continued to 
express RFP (Figure 4.1E-G and Figure 4.2B) (Yu et al., 2015).  Furthermore,  
the percentage of YFP+ cells expressing RFP was similarly high at three and 
seven months post treatment (Figure 4.1E,F).  These results indicated T-bet  
expression in YFP-labeled Treg cells to be remarkably stable as it was in 
effector CD4 T cells (Figure 4.1G). 
 At the same time, YFP-tagged Treg cells as a percent of total Treg cells 
decreased dramatically between the three week and seven month time points, 
particularly in non-lymphoid tissues even as the relative T-bet-expressing 
(RFP+) cell population size remained the same (Figure 4.1F).  Thus, in 
contrast to the bulk peripheral Treg cell pool in adult mice, which is largely 
self-sustaining (Rubtsov et al., 2010), continual Treg cell recruitment into the 
T-bet+ subset balances out rapid turnover of cells over time. 
 
An unstable T-betlo intermediate precedes stable T-bet expression in 
Treg cells  
The presence of small percentages of YFP+RFP- cells lacking T-bet three 
weeks post gavage (Figure 4.1E,F) suggested that some Treg cells, in which 
T-bet expression had been induced at the time of, or immediately prior to 
tamoxifen administration, might have subsequently become T-bet (RFP)- due 
to a transient unstable T-bet expression.  Such a scenario would reconcile the 
above result with the aforementioned previously published study, in which 
highly efficient recombination mediated by a Tbx21 BAC transgene-encoded 
CreERT2 revealed considerable instability of T-bet expression in Treg cells 
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(Yu et al., 2015).  Indeed, we observed that the T-bet expressing (RFP+) Treg 
cell population in Tbx21RFP-CreERT2 mice contained an RFPlo cell subset, which 
did not express the T-bet-dependent chemokine receptor CXCR3, and 
RFPhiCXCR3+ cells (Figure 4.3A).  Although both populations expressed high 
levels of CD44, indicating TCR-dependent peripheral activation (Levine et al., 
2014; Vahl et al., 2014), CD44 MFI was slightly higher whereas CD62L 
expression was slightly lower on T-bethi (RFPhi) CXCR3+ cells suggesting that 
the latter represented a more differentiated T-bet+ Treg cell state, whereas T-
betlo (RFPlo) CXCR3- cells were likely a transient differentiation intermediate 
(Figure 4.3B,C).  Consistent with this possibility, ~40% of FACS-sorted 
RFPloCXCR3- Treg cells lost RFP expression within 14 days following transfer 
into lymphoreplete hosts, whereas 17% up-regulated T-bet to become 
RFPhiCXCR3+ (Figure 4.3D, E).  In contrast, the vast majority of Tbethi (RFPhi) 
CXCR3+ Treg cells retained high T-bet expression.  Importantly, the fact that 
transferred bulk T-bethi Treg cells behaved the same in terms of stability of T-
bet expression as YFP-labeled Treg cells in intact Tbx21RFP-CreERT2 mice 
indicates that YFP-labeled cells accurately represent the T-bethi population on 
the whole.  Notably, populations of RFPloCXCR3- and YFP+RFP- cells were 
also observed within the CD4+Thy1.1- non-Treg cell population (Figure 4.3A), 
suggesting that rather than belying unique instability of T-betlo Treg cells they 
instead are indicative of the general, gradual process of peripheral CD4+ T cell 
effector differentiation, consistent with studies demonstrating up-regulation of 
both GATA3 and T-bet prior to eventual TH1 or TH2 differentiation or RORγt 
and Foxp3 prior to TH17 or Treg cell commitment (Hwang et al., 2005; Zhou et 
al., 2008).  Indeed, RNA-seq analysis revealed the characteristic gene 
expression pattern of CD44hiRFPloCXCR3- Treg cells to be intermediate  











Figure 4.3.  T-betlo cells likely represent a transient unstable 
intermediate in the differentiation of stably T-bethi Treg cells.  
A, Representative flow cytometric analysis of the indicated cell subsets, gated 
on TCRβ+ PBS-57-CD1d tetramer- CD4+ cells. B-C, CD44 median 
fluorescence intensity (MFI) on (B) and percent CD62Lhi (C) RFP-CXCR3- 
(gray shaded histogram and squares), RFPloCXCR3- (open black histogram 
and squares), and RFPhiCXCR3+ (open red histogram and squares) TCRβ+ 
PBS-57-CD1d tetramer- CD4+ Thy1.1+ splenic cells. D, CD62LhiCD44loRFP-, 
CD44hiRFP-, CD44hiRFPloCXCR3-, and CD44hiRFPhiCXCR3hi Thy1.1+ cells 
were FACS-sorted and transferred into lymphoreplete hosts. Flow cytometric 
analyses show Thy1.1+ cells of the indicated sorted subsets (above) from 
pooled spleens and lymph nodes 14 days after transfer. E, Quantification of 
data in (D).  p values were calculated using Student’s t test (*** denotes p 
values <0.001).  The data is representative of 2 independent experiments with 
at least 5 mice each (A-C) or represent the combined results from two 
independent experiments with at least 2 mice per group each (D,E).  F, 
Differential RNA expression between CD44hiRFP- and CD44hiRFPhiCXCR3+ 
Treg cells sorted from pooled spleens and lymph nodes of Tbx21RFP-CreERT2 
mice. All genes significantly up- or down-regulated are indicated in red and 
blue.  The number of genes significantly up (red) or down (blue) in 
CD44hiRFPhiCXCR3+ vs CD44hiRFP- are indicated.  G, Expression of the 288 
genes up ≥ 1.5-fold (left) or 184 genes down ≤ 1.5-fold (right) in 
CD44hiRFPhiCXCR3+ vs. CD44hiRFP- cells.  For (G), genes with a mean 
expression value < 15 were excluded from analysis.  p values were calculated 
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between that of CD44hiRFP- cells lacking T-bet expression and 
CD44hiRFPhiCXCR3+ cells (Figure 4.3F,G).  Together, these studies indicate 
that following peripheral activation, some Treg cells upregulate T-bet, and after 
passing through an intermediate state with unstable and relatively low levels of 
T-bet expression, differentiate into TH1-like Treg cells characterized by stable 
and heritable expression of high amounts of T-bet. 
 
Stable T-bet expression in Treg cells during TH2-polarizing infection 
These results raised the question of whether the observed stability of T-bet 
expression in Treg cells at steady state in mice on a TH1-prone C57BL/6 
genetic background would be maintained under polarizing conditions 
promoting an alternative effector CD4 T cell fate.  To address this question, we 
performed fate mapping in Tbx21RFP-CreERT2 mice during Nippostrongylus  
brasiliensis (Nb) infection, known to induce a strongly TH2-polarized systemic 
and local immune response, and assessed whether T-bet+ Treg cells would 
continue to retain or would instead lose T-bet expression.   
 Accordingly, we treated Tbx21RFP-CreERT2 mice with tamoxifen to tag a 
cohort of T-bet+ Treg cells with YFP three weeks prior to infection and 
analyzed mice at the peak of the T cell response (Figure 4.4A).  We reasoned 
that if pre-existent T-bet+ Treg cells were “plastic” and down-regulated T-bet 
during Nb infection, the percent T-bet (RFP)- of YFP+ Treg cells would notably 
increase—while the percent RFP+ of YFP-tagged Treg cells would decrease—
in infected compared to control uninfected mice.  By day 9, robust T cell 
activation (and production of the TH2 cytokines IL-4, IL-13, and IL-5) was 
apparent in spleens and lungs of infected mice, with dramatically increased 
percentages of CD44hi CD4 T cells that predominantly, as expected, did not  




Figure 4.4.  Stability of the TH1-like phenotype during helminthic 
infection.  
A, Schematic of experiments combining tamoxifen treatment with Nb infection 
in Tbx21RFP-CreERT2 mice.  B, Representative flow cytometry of splenic (above) 
and lung (below) TCRβ+ PBS-57-CD1d tetramer- CD4+ Thy1.1- cells of control 
PBS-treated (left) and Nb-infected (right) mice.  C, Quantification of the 
percent RFP+ cells among YFP+ TCRβ+ PBS-57-CD1d tetramer- CD4+ Thy1.1+ 
cells in control PBS-treated (white circles) and Nb-infected (black circles) 
mice.  D, Representative histograms of RFP expression on total TCRβ+ PBS-
57-CD1d tetramer- CD4+ Thy1.1+ (shaded histograms) or Th1.1+YFP+ (open 
histograms) cells from spleens of Nb-infected (red) or PBS-treated control 
(black) mice.  Each circle represents an individual mouse; the horizontal bars 
represent mean value; p values were calculated using Student’s t test (***, **, 
and * denotes p values <0.001, 0.01, and 0.05, respectively); the data shown 
represent the combined results of 2 independent experiments with at least 3 
mice per group each. 
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express T-bet (RFP) (Figure 4.4B, data not shown).  Strikingly, YFP-labeled 
Treg cells demonstrated no decrease in RFP expression, either as a 
percentage of YFP+ cells or on a per cell basis (Figure 4.4C,D).  This was the 
case despite Treg cell activation in response to infection evidenced by 
increased percentages of CD44hiCD62Llo Treg cells in Nb challenged 
compared to control mice (data not shown).  Similar stability of T-bet 
expression was observed for effector CD4 T-bet (RFP)+ T cells (data not 
shown).  These data indicate that T-bet expression in Treg cells did not 
represent a readily reversible activation state.  Instead, YFP-marked T-bet-
expressing Treg cells exhibited intrinsic stability typical of a differentiated cell 
state even in face of type 2 inflammation caused by helminthic infection 
promoting an alternative effector T cell fate. 
 
De novo differentiation of T-bet+ Treg cells upon TH1-polarizing infection 
The idea of peripheral differentiation of steady state T-bet+ Treg cells in 
response to “self” was consistent with their numbers in spleens and lymph 
nodes being unaltered upon antibiotic treatment (see below) and with a recent 
report that these cells were comparably prominent in the secondary lymphoid 
organs in germ-free mice on an antigen-free diet and in control mice (Kim et 
al., 2016).  In addition to these steady state cues, infection with intracellular 
pathogens can also increase numbers of T-bet+ Treg cells (Hall et al., 2012; 
Koch et al., 2012; Shafiani et al., 2013).  These findings raise the question 
whether infection-associated increases in the T-bet+ Treg cell subset represent 
an expansion of the pre-existent pool or de novo differentiation from T-bet-
negative Treg precursors, and whether these processes result in a stable or 
reversible T-bet expression. 
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To answer these questions we performed fate-mapping studies in 
Tbx21RFP-CreERT2 mice during intracellular bacteria Listeria monocytogenes 
(Lm) infection, previously demonstrated to increase numbers of T-bet+ Treg 
cells which were notably pathogen non-specific (Ertelt et al., 2009; Shafiani et 
al., 2013).  Consistent with previous reports, Lm infection increased the 
proportion and absolute numbers of T-bet (RFP) expressing Treg cells in the 
spleen and liver (Figure 4.5B,C and data not shown) (Koch et al., 2012).  To 
determine the origin of these Lm infection-induced T-bet (RFP)+ cells we 
treated Tbx21RFP-CreERT2 mice with tamoxifen to tag a cohort of T-bet+ Treg 
cells with YFP three weeks prior to infection and analyzed mice at the peak of 
the T cell response (Figure 4.5A).  We reasoned that if the pre-existent T-bet+ 
Treg cell pool expanded in response to infection, the percent YFP-tagged Treg 
cells would increase in parallel to the increase in T-bet (RFP)+ cells; on the 
other hand, if the percent RFP+ cells increased while the percent YFP+ cells 
did not, this would imply that infection induced up-regulation of T-bet in 
previously T-bet- Treg cells. 
Upon Lm challenge, splenic and liver subsets of T-bet (RFP)+ Treg cells 
and effector T-bet (RFP)+ CD4+ T cells increased markedly; however, the 
proportion of YFP+ cells remained unchanged in both populations (Figure 
4.5B-D).  This pattern was indicative of de novo differentiation of T-bet+ Treg 
cells from T-bet- Treg precursors in parallel with the expected differentiation of 
effector TH1 cells from naïve T cells.  It is important to note that—as opposed 
to Nb infection—T-bet+ Treg cells tagged with YFP prior to Lm infection were 
exposed to, and did sense, TH1 inflammation as evidenced by increased T-bet 
and CXCR3 expression on a per cell basis despite the fact that the relative 
proportion of YFP+ T-bet+ Treg cells did not increase (Figure 4.5E).  However,  










Figure 4.5. Listeria monocytogenes infection drives de novo 
differentiation of T-bet-expressing Treg cells.  
A, Schematic of the experiments combining tamoxifen (tx) treatment with Lm 
infection in Tbx21RFP-CreERT2 mice. B, Representative flow cytometry analysis of 
splenic TCRβ+ PBS-57-CD1d tetramer- CD4+ Thy1.1+ (left) and Thy1.1- (right) 
cells of control PBS-treated (above) and Lm-infected (below) mice. Numbers 
indicate percent RFP+ and YFP+ cells. C-D, Quantification of percent RFP+ 
(top) and YFP+ (middle) cells and the YFP+/RFP+ ratio (below) for Thy1.1+ (C) 
and Thy1.1- (D) CD4+ cells in spleens and livers of experimental and control 
mice. E, Representative histograms of RFP and CXCR3 expression on total 
TCRβ+ PBS-57-CD1d tetramer- CD4+ Thy1.1+ (shaded histograms) or 
Th1.1+YFP+ (open histograms) cells from spleens of Lm-infected (red) or PBS-
treated control (black) mice.  F-H, Analysis of IL-10eGFP expression in 
Tbx21RFP-CreERT2IL-10eGFP mice treated with tx and challenged with Lm or PBS 
as in (A). F, Flow cytometry plots gated on splenic TCRβ+ PBS-57-CD1d 
tetramer- CD4+ Thy1.1+ (above) and Thy1.1+YFP+ (below) cells in PBS (left) 
and Lm (right) treated mice. G, Percent RFP-eGFP+ and RFP+eGFP+ cells 
among Thy1.1+ cells, as gated in (F, above).  H, Percent eGFP+ cells among 
Thy1.1+YFP+ cells, as gated in (F, below).  I-J, T-bet fate mapping during Lm 
infection. I, Schematic of experimental setup. CD62LhiCD44loRFP-, 
CD44hiRFP-, and CD44hiRFPhiCXCR3hi Thy1.1+ cells were FACS-sorted from 
pooled spleens and lymph nodes of Tbx21RFP-CreERT2 mice and transferred into 
lymphoreplete hosts one day before i.v. injection of Lm or PBS control. J, 
Representative flow cytometry plots of Thy1.1+ cells in spleens of PBS-treated 
(left) or Lm-infected (right) host mice on day 9.  Transferred cell populations 
are indicated on the left.  Each circle or square represents an individual 
mouse; the horizontal bars represent mean value; p values were calculated 
using Student’s t test (ns – not significant, denotes p value > 0.05); the data 
shown represent the combined results of 2 independent experiments with at 
least 5 mice per group each (B-D), or 2 experiment with 4 mice per group each 
(F-H), or 2 experiments with at least 2 mice per group each. 
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this increase in T-bet MFI and CXCR3 expression was not associated with 
obviously increased expression of effectors of suppressor function, as 
exemplified by the fact that the same fate mapping strategy applied to 
Tbx21RFP-CreERT2IL-10eGFP/WT mice expressing previously described eGFP as a 
transcriptional IL-10 knock-in reporter revealed no increase in IL-10eGFP+ cells 
among pre-labeled Thy1.1+YFP+ cells even as total percentages of RFP+IL-
10eGFP+ Treg cells increased ~3-fold (Figure 4.5F-H)(Kamanaka et al., 2006).  
Similar results were obtained during lymphocytic choriomeningitis virus 
(LCMV) infection (data not shown), suggesting this to be a general—rather 
than Lm-specific—phenomenon of Treg cell responsiveness to acute infection 
with TH1-polarizing pathogens. 
To determine whether “naïve” or activated T-bet (RFP)- Treg cell 
subsets gave rise to Lm-induced RFP+ cells, we purified by FACS naïve-like 
CD44loCD62Lhi T-bet (RFP)- and effector-like CD44hiRFP- Treg cells and 
transferred them into congenically-marked lymphoreplete hosts one day 
before Lm infection (Figure 4.5I).  We found that both CD44loCD62Lhi and 
CD44hi T-bet (RFP)- Treg cell subsets differentiated into RFP+CXCR3+ cells in 
response to infection (Figure 4.5J).  Thus, the increase in T-bet+ Treg cells 
observed following Lm infection appears to be the result of both naïve and 
effector T-bet- Treg cell differentiation into T-bet+ Treg cells. 
 
Persistence of Lm-induced TH1-like Treg cells following resolution of 
infection 
We next assessed whether Treg cells that upregulated T-bet and expanded 
during Lm infection would persist over time following resolution of infection and 
whether these cells were capable of mounting a recall response upon re-
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infection.  To address this question, we administered tamoxifen at the peak of 
the primary response to Lm infection (days 7 and 9) to preferentially label 
infection-induced T-bet+ cells (data not shown) and assessed mice two months 
later, at which time the percent of splenic and liver Treg cells that were T-bet+ 
had returned to roughly pre-infection levels (Figure 4.6A,B).  As the T-bet+ 
Treg cell pool is subject to considerable turnover in the course of two months 
(Figure 4.1), we reasoned that by day 60 post infection YFP+ cells labeled at 
the peak of infection would be relatively enriched for infection-induced T-bet 
(RFP)+ Treg cells compared to the bulk RFP+ cell pool. 
 As expected, reinfection with Lm dramatically increased bulk effector T-
bet+ CD4 T cells and even more prominently increased the subset of cells 
tagged with YFP during primary infection, consistent with expansion of 
memory cells driving secondary increases in T-bet+ cells (Figure 4.6C).  
Likewise, following secondary challenge we also observed an increase in T-
bet+ Treg cells, albeit less pronounced than that of effector CD4 T cells, with a 
similarly preferential expansion of YFP-tagged cells (Figure 4.6B).  Consistent 
with the idea that secondary infection can cause reactivation of specifically T-
bet+ Treg cells, RFP+IL10eGFP+ but not RFP-IL10eGFP+ cells in Tbx21RFP-
CreERT2IL-10eGFP/WT mice increased upon rechallenge as they did during primary 
infection (Figure 4.6F,G).  These results indicated that infectious episodes, by 
eliciting differentiation of distinctly responsive T-bet+ Treg cells, further 
contribute to Treg cell heterogeneity. 
To determine whether T-bet expression in these infection-induced T-
bet+ Treg cells was a stable feature of differentiation or was a reversible 
consequence of their activation secondary to infectious challenge conditions, 
we assessed RFP expression in YFP+ Treg cells that had been labeled at the 












Figure 4.6. Stable differentiation of TH1-like effector Treg cells in 
response to L. monocytogenes infection.  
A, A schematic of T-bet fate mapping during Lm infection; Tbx21RFP-CreERT2 
mice were infected i.v. with Lm or injected with PBS (control) on day 0, 
gavaged with tx on days 7 and 9 (B-D) or on days 37 and 39 (E); mice were 
re-infected with Lm or PBS on day 60, and analyzed on day 65.  B-C, Percent 
RFP+ (top) and YFP+ (middle) cells and the YFP+/RFP+ ratio (below) for 
Thy1.1+ (B) and Thy1.1- (C) CD4+ cells in spleens and livers of mice treated 
with tx on days 7 and 9. D, Percent RFP+ of CD4+Thy1.1+YFP+ cells. E, 
Percent RFP+ (top) and YFP+ (middle) cells and the YFP+/RFP+ ratio (below) 
for Thy1.1+ CD4+ cells in spleens and livers of mice treated with tx on days 37 
and 39. F-G, Tbx21RFP-CreERT2IL-10eGFP mice were challenged with Lm or PBS 
on day 0, rechallenged with PBS or Lm on day 60 and analyzed on day 65.  
Representative flow cyotometry plots gated on the indicated populations in 
Tbx21RFP-CreERT2IL-10eGFP mice, treated as indicated on the left. G, Percent 
RFP-eGFP+ and RFP+eGFP+ cells among Thy1.1+ cells, as gated in (F).  Each 
circle or square represents an individual mouse; the horizontal bars represent 
mean value; p values were calculated using Student’s t test (***, **, and * 
denotes p values <0.001, 0.01, and 0.05, respectively; ns – not significant). 
The data represent the combined results from 4 independent experiments with 
at least 3 mice per group each (B-D) or combined results from 2 independent 
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peak of the primary immune response to Lm.  On day 65 following primary Lm 
infection, 91% and 94% of splenic and liver YFP+ Treg cells continued to 
express T-bet, respectively, compared to 92% and 94% of splenic and liver 
YFP+ Treg cells, respectively, in control PBS treated mice (Figure 4.6D).  This 
finding strongly suggested that Treg cells which had become T-bet+ during 
primary infection had maintained its expression following pathogen clearance 
and resolution of inflammation.  To formally demonstrate this proposition, we 
infected mice with Lm and administered tamoxifen on days 37 and 39 
following primary infection, three weeks prior to re-infection (Figure 4.6A).  We 
reasoned that if expansion of T-bet+ cells following secondary challenge was 
dependent on cells that acquired T-bet expression during primary infection and 
remained T-bet positive, reinfection would result in a parallel increase in bulk 
RFP+ and YFP+ Treg cell subsets, which indeed was the case (Figure 4.6E).  
Together, these studies demonstrate that bacterial infection did not expand a 
pre-existent, steady-state pool of T-bet + Treg cells, but caused de novo 
differentiation of T-bet- Treg cells into stable T-bet-expressing Treg cells 
uniquely suited for reactivation under conditions that drove their initial 
acquisition of T-bet.  These results suggest that steady state differentiation in 
response to self-antigens and differentiation during infectious episodes 
represent two independent sources contributing to the population of T-bet+ 
Treg cells. 
 
T-bet ablation in Treg cells causes only a mild defect in suppressor 
function  
Continuous peripheral generation of T-bet+ Treg cells at steady state (Figure 
4.1F) seemed to imply a particular function for T-bet+ Treg cells in suppression 
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of spontaneous autoimmunity under physiologic conditions presumably 
imparted by T-bet itself.  However, several studies have failed to identify 
changes in immune status upon ablation of a conditional Tbx21 allele in Treg 
cells at steady state or in response to a variety of challenges (Colbeck et al., 
2015; McPherson et al., 2015; Yu et al., 2015). To revisit this issue, we 
generated and analyzed Foxp3YFP-CreTbx21FL/FL mice (Figure 4.7) (Intlekofer et 
al., 2008; Rubtsov et al., 2008). Although at 3 months of age these mice were 
healthy and clinically indistinguishable from littermate controls, they did exhibit 
mild TH1 immune activation, with increased CD44hi and CXCR3+ CD4 T cell 
percentages (from 26% to 41% and 15% to 26%, respectively) and a selective 
two-fold increase in IFNg-producing CD4+ T cells, whereas IFNg production by 
CD8+ T cells and IL-2, IL-4, and IL-17 production by CD4+ T cells remained 
unaffected (Figure 4.7).  Thus, in our hands, in contrast to previous reports, T-
bet expression moderately potentiates the ability of Treg cells to suppress 
spontaneous TH1-type immune activation in unchallenged mice. 
 
T-bet+ Treg cells restrain severe TH1-dependent autoimmune disease 
It remained possible that T-bet deficiency in Treg cells, resulting in a mild 
increase in TH1 responses and lacking clinical sequelae, may not fully reflect 
the functional importance of TH1-like Treg cells, which may have a broader, 
but T-bet independent role in maintaining tolerance.  We considered the 
possibility that T-bet+ Treg cells may possess a distinct TCR repertoire that 
may allow them to suppress particular autoimmune responses even in the 
absence of T-bet induced gene expression and CXCR3-mediated localization.   
To test this idea, we sorted CD44hiCXCR3 (T-bet)+ and CD44hiCXCR3 (T-bet)- 




Figure 4.7. Mildly increased TH1 cytokine production by T cells in mice 
lacking T-bet expression in Treg cells.  
A, Representative flow cytometry plots of CD4+ TCRβ+ PBS-57-loaded CD1d 
tetramer- cells in spleens of the indicated 2-3 month old mice. B, T cell 
activation, CXCR3 expression, and cytokine production in control Foxp3YFP-
CreTbx21WT/WT and Foxp3YFP-CreTbx21FL/WT (white circles) and experimental 
Foxp3YFP-CreTbx21FL/FL (black circles) mice.  Each circle represents an 
individual mouse; error bars indicate SEM; p values were calculated using 
Student’s t test (* denotes p value < 0.05; ns – not significant).  The data 







  119 
 
Treg and CD4 effector T cells from Tcra+/- mice expressing a Foxp3 reporter 
and the DO11.10 TCRβ chain transgene so that TCR diversity is limited to a 
single functional TCRα chain locus (Feng et al., 2015).  Indeed, TCR 
repertoires in CD44hiCXCR3+ and CD44hiCXCR3- Treg cell populations were 
distinct—unlike TCR repertoires in the effector T cell populations—suggesting 
that preferential recognition of particular antigens by T-bet+ Treg cells may, in 
addition to their unique transcriptional program and migratory properties, be an 
essential determinant of their suppressor capacity (Figure 4.8). 
 Therefore, we sought to determine the effect of eliminating the T-bet+ 
Treg cell population in its entirety.  Since Treg cell suppressor function 
requires continuous expression of the Foxp3 gene we generated Tbx21tdTomato-
T2A-Cre knock-in mice (Figure 4.9A) and performed the reverse experiment to 
deleting T-bet in Foxp3-expressing cells, i.e. ablating Foxp3 expression in T-
bet-expressing Treg cells.  Indeed, Cre-mediated loss of Foxp3 expression in 
T-bet+ Treg cells in male Tbx21RFP-Cre/RFP-CreFoxp3FL (hereafter referred to as 
Tbx21RFP-CreFoxp3FL) mice resulted in a failure to thrive reflected in a 
decreased weight gain, a variable, patchy loss of hair pigmentation, and 
marked immune infiltration and pathology in the lung (Figure 4.10A,B and 
Figure 4.9B).  These mice exhibited pronounced lymphadenopathy and T cell 
activation in the spleen, lymph nodes, and lungs when compared to littermate 
controls (Figure 4.10C,D and Figure 4.9).  While significantly depleted of 
CXCR3+ cells, neither total Treg cell numbers nor numbers of CD44hiCD62Llo 
effector Treg cells were diminished (Figure 4.10E and Figure 4.9H).   
Importantly, this indicates that deletion of Foxp3 in some ‘exT-bet+’ Treg cells 
that had only transiently expressed low levels of T-bet and Cre recombinase  





Figure 4.8. T-bet+ CD44hiCXCR3+ Treg cells have a distinct TCR 
repertoire.   
Dendrogram showing clustering of TCR sequences in CD44hiCXCR3+ Treg 
(treg pos) and CD44hiCXCR3- Treg (treg neg) as well as CD44hiCXCR3+ 
effector (teff pos) and CD44hiCXCR3- effector (teff neg) T cell populations 
sorted from spleens (spl) and axial/brachial/cervical/inguinal lymph nodes (ln) 
of DO11.10 TCRβ+ Tcra+/- Foxp3 reporter mice.  Sample preparation and 
statistical analyses are described in the Methods section.  Pearson correlation 
of clonotype frequencies for the shared TCR clones was used for the 
generation of the dendrogram. 
 










Figure 4.9. Generation and analysis of Tbx21RFP-CreFoxp3FL mice.  
A, Targeting strategy for the Tbx21 locus (above) and RFP expression in the 
indicated cell populations in spleens of homozygous Tbx21RFP-Cre/RFP-Cre mice 
(below).  B, Representative patchy loss of hair pigmentation in 8-week old 
Tbx21RFP-CreFoxp3FL mouse compared to a littermate male control. C, 
Representative flow cytometry analysis of the indicated populations in 
Tbx21RFP-CreR26Y mice. D-E, Percent CD44hi of CD4+Foxp3-CD25- cells (left) 
and percent CD44hiRFP- and CD44hiRFP+ CD4+CD25- cells (right) in pooled 
axial/brachial/cervical/inguinal lymph nodes (D) and lungs (E) of the indicated 
mice. F, Percent CD44hiCD62Llo of CD8+ T cells in lymph nodes (left) and 
lungs (right) of the indicated mice. G, Cytokine production by CD4+Foxp3- and 
CD8+ T cells in lungs.  H, Percent CXCR3+ of CD4+Foxp3+ cells (left), and 
absolute numbers of CD4+Foxp3+ (middle) and CD44hiCD62Llo Foxp3+ (right) 
cells in lymph nodes. I, Percent Foxp3-CD25+ of CD4+ cells in spleen (left), 
lymph nodes (middle), and lung (right) of mice of the indicated genotypes. J, 
Representative flow cytometric analysis of cells gated on CD4+ TCRβ+ PBS-
57-CD1d tetramer- splenic cells, as quantified in (I). Numbers indicate the 
percent Foxp3-CD25+. K, Representative histograms showing expression of 
Treg cell signature molecules in CD4+Foxp3-CD25+ cells in spleens of 
Tbx21RFP-CreFoxp3WT (open gray histogram), Tbx21RFP-CreFoxp3FL (open red 
histogram), Tbx21RFP-CreFoxp3WT/WT (open blue histogram), and Tbx21RFP-
CreFoxp3FL/WT (open black histogram) mice.  CD4+Foxp3+CD25+ cells from a 
Tbx21RFP-CreFoxp3WT (shaded gray histogram) mouse are shown as a point of 
reference.  Each circle represents an individual mouse; the horizontal bars 
represent mean value; p values were calculated using Student’s t test (***, **, 
and * denotes p values <0.001, 0.01, and 0.05, respectively; ns – not 
significant). The data represent the combined results from several 
independent experiments. 
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Figure 4.10. Foxp3 ablation in T-bet+ Treg cells results in severe 
spontaneous TH1 autoimmune disease.  
A, Analysis of body weights of 8-10 week old Tbx21RFP-CreFoxp3WT (gray 
circles), Tbx21RFP-CreFoxp3FL (red circles), Tbx21RFP-CreFoxp3WT/WT (blue 
circles), and Tbx21RFP-CreFoxp3FL/WT (white circles) mice. B, Representative 
H&E staining (left) and histology scores (right) of lungs from the indicated 
mice, treated or not treated with antibiotics (ABX). Tbx21RFP-CreFoxp3FL mice 
show moderate perivascular and peribronchiolar inflammation, mild respiratory 
epithelial hyperplasia and mucus metaplasia with hyalinization (arrows).  
Pulmonary arterioles are contracted with thickened media, reactive endothelia, 
and marginating leukocytes (arrowheads). Original magnification, 20x. C, 
Lymph node cell numbers in mutant and control mice. D, CD4+Foxp3-CD25- 
(left) and CD8+ (right) T cell activation in spleens. E, Percent CXCR3+ of 
Foxp3+ (left), and absolute numbers of Foxp3+ (middle) and CD44hiCD62Llo 
Foxp3+ (right) T cells in spleens. F, Representative flow cytometric analysis of 
splenic cells in Tbx21RFP-CreFoxp3WT (left) and Tbx21RFP-CreFoxp3FL (right) 
mice, gated on fixed CD4+ TCRβ+ PBS-57-CD1d tetramer- (above) and live 
CD4+ TCRβ+ PBS-57-CD1d tetramer- CD25- (below) cells. Numbers indicate 
percentages of the indicated cell subsets. G, Quantification of percentages of 
splenic CD44hiRFP- and CD44hiRFP+ CD4+CD25- cells, as shown in (F, 
bottom). H, RFP expression (left) and cytokine production (right) in splenic 
CD8+ T cells in Tbx21RFP-CreFoxp3WT (gray histogram) and Tbx21RFP-
CreFoxp3FL (red histogram), Tbx21RFP-CreFoxp3WT/WT (blue histogram) and 
Tbx21RFP-CreFoxp3FL/WT (black histogram) mice. I, Cytokine production by 
splenic CD4+Foxp3- T cells.  Each circle represents an individual mouse; error 
bars indicate standard error of the mean (SEM); p values were calculated 
using Student’s t test (***, **, and * denotes p values <0.001, 0.01, and 0.05, 
respectively; ns – not significant). The data represent the combined results 
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(Figure 4.3) did not prevent activation and expansion of CD44hi effector Treg 
cells that did not express T-bet.  Indeed, analysis of CD4+CD25+ cells in 
Tbx21RFP-CreR26Y mice indicated that—even in the absence of inflammation 
that likely promoted expansion of T-bet- CD44hiCD62Llo Treg cells in Tbx21RFP-
CreFoxp3FL mice—significant percentages of CD44hiCD62Llo Treg cells had not 
undergone Cre-mediated recombination (Figure 4.9C).  We confirmed by 
intracellular staining that residual CXCR3+ Treg cells in Tbx21RFP-CreFoxp3FL 
mice expressed T-bet (data not shown), indicating that even some T-bet+ Treg 
cells, likely T-betlo cells—a significant percentage of which remain YFP- in 
Tbx21RFP-CreR26Y mice (Figure 4.9C)—escape Cre-mediated recombination.  
These results suggested that immune activation could not be attributed to 
decreased numbers of Treg cells, or even to wholesale loss of effector-like 
Treg cells. 
 Foxp3- ex-Treg cells expressing high levels of Treg cell signature genes 
coding for a number of molecules including CD25, CD39, CTLA4, and GITR 
were readily found in spleens and lymph nodes of male Tbx21RFP-CreFoxp3FL 
(and to a lesser extent female Tbx21RFP-CreFoxp3FL/WT) mice, confirming the 
essential role of continuous Foxp3 expression in Treg cells for suppressive 
function (Figure 4.10F and Figure 4.9I-K) (Gavin et al., 2007; Lahl et al., 2009; 
Williams and Rudensky, 2007).  The fact that there was no detectable 
autoimmunity in female Tbx21RFP-CreFoxp3FL/WT mice—in which only half of T-
bet+ Treg cells lose Foxp3 expression due to X-inactivation—suggested that 
ex-Treg cells were unable to cause autoimmunity in a strictly cell-intrinsic 
manner as they could be controlled by a competent population of T-bet+ Treg 
cells (in the same way that ‘wannabe’ Foxp3KO Treg cells in female Foxp3WT/KO 
mice are effectively controlled by Foxp3+ Treg cells present in the same mice 
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(Figure 4.10).  However, it is additionally possible that ex-Treg cells may play 
some role in the observed autoimmune activation in Tbx21RFP-CreFoxp3FL mice 
lacking T-bet-expressing Treg cells. 
 Indicative of TH1-type inflammation, the majority of expanded, activated 
CD44hi CD4+CD25- and CD8+ T cells in the spleen, lymph nodes, and lung of 
Tbx21RFP-CreFoxp3FL mice expressed T-bet (RFP) (Figure 4.10F-H and Figure 
4.9).  Additionally, IFNg production by both CD4 and CD8 T cells and IL-2, but 
neither IL-4 nor IL-17 production by CD4 T cells were increased in spleens 
and lungs compared to controls (Figure 4.10H,I and Figure 4.9).  To determine 
whether TH1 inflammation was driven by microbiota, Tbx21RFP-CreFoxp3FL mice 
were treated from the time of weaning with a broad spectrum cocktail of 
antibiotics and analyzed at two months of age.  Antibiotic treatment did not 
mitigate weight loss, systemic immune activation, or lung pathology in 
Tbx21RFP-CreFoxp3FL mice compared to antibiotic treated Tbx21RFP-CreFoxp3WT 
controls and untreated experimental and control groups (Figure 4.10B and 
data not shown).  This result suggested that most likely “self”, dietary, and 
other environmental rather than microbial antigens were the drivers of TH1 
inflammation and disease upon the loss of function of T-bet+ Treg cells. 
Although Treg cells in Tbx21RFP-CreFoxp3FL mice efficiently controlled 
TH2 and TH17 cytokine production at steady state, basal production of these 
cytokines is relatively low in C57BL/6 mice; therefore, we considered whether 
induction of a robust “non-TH1” immune response in Tbx21RFP-CreFoxp3FL mice 
might reveal a function for T-bet+ Treg cells in control of these responses. 
Accordingly, we challenged Tbx21RFP-CreFoxp3FL and littermate controls with 
Nippostrongylus brasiliensis and assessed immune activation on day 9.  We 
found that the TH2 response—as assessed by eosinophilia in the lung, and 
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percentages of GATA3+ and IL-4, -13, and -5-producing CD4+ T cells in spleen 
and lungs—was not increased and remained essentially indistinguishable in 
Tbx21RFP-CreFoxp3FL compared to control Tbx21RFP-CreFoxp3WT mice (Figure 
4.11).  This is in contrast to increased TH2 responses observed upon general 
Treg cell depletion in helminth-infected mice (Blankenhaus et al., 2014; 
Sawant et al., 2014; Smith et al., 2016).  Thus, T-bet+ Treg cells appear to be 
largely dispensable for control of TH2 immunity, consistent with the notion that 
T-bet+ Treg cells are preferentially—if not selectively—involved in control of 
TH1 responses. 
 Lastly, to determine whether punctual ablation of T-bet+ Treg cells in 
adult mice would similarly unleash TH1-type inflammation, we generated 
chimeric mice by reconstituting irradiated T cell-deficient TcrbKOTcrdKO mice 
with a 1:1 mix of either CD45.1+ Foxp3WT or Foxp3KO with CD45.2+ Tbx21RFP-
Cre/WTRosa26iDTR hematopoietic precursor cells (Figure 4.12).  All T-bet 
expressing hematopoietic cells originating from Tbx21RFP-Cre/WTRosa26iDTR 
precursors expressed diphtheria toxin receptor (DTR) due to Cre-mediated 
excision of a loxP site-flanked STOP cassette in front of the simian DTR 
coding sequence inserted into the Rosa26 locus (Buch et al., 2005).  Thus, in 
Foxp3KO + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO mixed chimeras all T-
bet+ Treg cells expressed DTR and were, therefore, susceptible to diphtheria 
toxin (DT)-mediated ablation, whereas the rest of T-bet expressing cell types 
and subsets represented a 1:1 mix of DTR-expressing and non-expressing 
cells.  Two weeks of daily DT administration resulted in weight loss, profound 
T cell activation, and a selective increase in IFNγ production by CD4 and CD8 
T cells in Foxp3KO + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO chimeric mice  
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Figure 4.11. The TH2 response to N. brasiliensis is not exacerbated in 
Tbx21RFP-CreFoxp3FL mice.   
Tbx21RFP-CreFoxp3FL and control Tbx21RFP-CreFoxp3WT mice were infected with 
Nb and analyzed on day 9 post challenge.  A, Representative flow cytometry 
plots showing GATA3 expression in CD4+Foxp3- T cells in spleens (above) 
and lungs (below) in Tbx21RFP-CreFoxp3WT (left) and Tbx21RFP-CreFoxp3FL (right) 
mice. B, Quantification of data in (A).  C, Numbers of eosinophils in lungs of 
the indicated mice. D, Cytokine production by CD4+Foxp3- T cells in spleens 
and lungs of the indicated mice.  Data shows a single experiment with at least 
5 mice per group.  Each circle represents an individual mouse; the horizontal 
bars represent mean value; p values were calculated using Student’s t test (* 
denotes p values < 0.05; ns – not significant).  













Figure 4.12. Acute ablation of T-bet+ Treg cells in adult mice results in 
TH1 immune activation.  
Lethally irradiated Tcrb-/-Tcrd-/- mice were reconstituted with a 1:1 mix of 
CD45.2+Tbx21RFP-Cre/WTRosa26iDTR T-cell depleted bone marrow cells with 
either CD45.1+Foxp3KO or CD45.1+Foxp3WT T-cell depleted bone marrow cells 
and rested for three months.  Mice were injected i.p. with 0.5μg diphtheria 
toxin (DT) on day 0, then treated daily with 0.1μg DT for 14 days before 
analysis.  A, Weight loss in Tbx21RFP-Cre/WTRosa26iDTR:Foxp3KO- vs. Tbx21RFP-
Cre/WTRosa26iDTR:Foxp3WT-reconstituted mice. B, Representative plots, gated 
on splenic CD4+ TCRβ+ cells (above) and CD4+ TCRβ+ Foxp3+ cells (below) in 
Tcrb-/-Tcrd-/- mice reconstituted with the indicated bone marrow cells. C, 
Representative flow cytometry analysis showing CD44 and CD62L expression 
in CD45.1+ and CD45.2+ CD4+Foxp3+ cell populations in the indicated mice. D, 
CD4+ and CD8+ T cell activation and cytokine production in Tcrb-/-Tcrd-/- mice 
reconstituted with the indicated bone marrow cells.  Each circle represents an 
individual mouse; error bars indicate SEM; p values were calculated using 
Student’s t test (ns – not significant). The data is representative of 2 
independent experiments with at least 6 mice per group each. 
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ablated of T-bet+ Treg cells compared to control Foxp3WT + Tbx21RFP-
Cre/WTRosa26iDTR -> TcrbKOTcrdKO mice (Figure 4.12).   
 Despite a competitive disadvantage of CD45.2+ DT-depleted Treg cells 
in Foxp3WT + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO mice (Figure 4.12B), 
Treg cells in Foxp3KO + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO mice as a 
percent of total CD4+ T cells were only modestly decreased (from 13±0.53 to 
11±0.82, p=0.022) compared to in control mice (Figure 4.12B).  Consistent 
with a highly activated and proliferative state, Treg cells in experimental mice 
had undiminished percentages of CD44hiCD62Llo and increased percentages 
of Ki67+ cells compared to Treg cells in control animals (Figure 4.12C data not 
shown), indicating that in these mice as in Tbx21RFP-CreFoxp3FL mice a 
nonselective decrease in effector Treg cells cannot account for the observed 
immune activation.  Indeed, even in Foxp3WT + Tbx21RFP-Cre/WTRosa26iDTR -> 
TcrbKOTcrdKO mice, a substantial fraction of CD45.2+ CD44hiCD62Llo Treg cells 
which had not expressed T-bet and thus had not been depleted by DT were 
readily apparent (Figure 4.12C).  Importantly, this experimental model did not 
generate the ex-Treg cells that were present in Tbx21RFP-CreFoxp3FL mice, 
providing additional evidence that these cells were not the sole drivers of 
pathology in the absence of T-bet+ Treg cells.  We cannot rule out the 
possibility that increased fractional loss of Treg cells early after DT treatment 
of Foxp3KO + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO compared to in 
Foxp3WT + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO mice may play some 
role in the observed immune activation in experimental mice.  However, the 
fact that there are no signs of TH2 or TH17 activation in these mice (Figure 
4.12D) is consistent with both our data from Tbx21RFP-CreFoxp3FL mice and 
with the notion that T-bet+ Treg cells play a particular role specifically in the 
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control over TH1 autoimmunity.  Conversely, non-specific partial depletion of 
Treg cells in Foxp3DTR mice, ablation of the TCR on Treg cells which 
disproportionally affects CD44hiCD62Llo Treg cells, or specific manipulation 
and depletion of the entire CD44hiCD62Llo effector Treg cell population all 
result in non-selective increases in TH2 and TH17, as well as TH1, activation 
(Levine et al., 2014; Luo et al., 2016).  Finally, it was noteworthy that weight 
loss was not observed in TcrbKO + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO 
mixed chimeras, in which all T-bet+ TCRαβ+ cells were simultaneously ablated 
along with T-bet+ Treg cells (Figure 4.13).  The latter observation 
demonstrated that T-bet-expressing effector αβT cells drive disease in the 
absence of T-bet+ Treg cells consistent with a prominent role of the latter in 
control of TH1 responses. 
 
Discussion 
In this study, we investigated the apparent heterogeneity of Treg cells—
namely, whether it results from Treg cell differentiation into different states with 
potentially distinct functions or merely reflects readily reversible ‘plastic’ states 
of activation within a homogenous effector Treg cell pool.   Our studies using a 
novel Tbx21 fate mapping allele revealed remarkable stability of T-bet 
expression in Treg cells acquired upon their differentiation after passing 
through an unstable intermediate stage. The observed resilience of T-bet 
expression in Treg as well as in effector CD4 T cells under TH2 polarizing 











Figure 4.13.  Wasting disease observed upon T-bet+ Treg cell ablation is 
driven by T-bet-expressing effector αβ T cells.  
Lethally irradiated Tcrb-/-Tcrd-/- mice were reconstituted with a 1:1 mix of 
CD45.2+Tbx21RFP-Cre/WTRosa26iDTR T-cell depleted bone marrow cells with 
either CD45.1+Foxp3KO, CD45.1+Foxp3WT, or CD45.2+TcrbKO T-cell depleted 
bone marrow cells and rested for three months. Mice were injected i.p. with 
0.5μg diphtheria toxin (DT) on day 0, then treated daily with 0.1μg DT for 22 
days before analysis. A, Weight loss in Tbx21RFP-Cre/WTRosa26iDTR:Foxp3KO 
(red line) vs. Tbx21RFP-Cre/WTRosa26iDTR:Foxp3WT (black line) vs. Tbx21RFP-
Cre/WTRosa26iDTR:TcrbKO (blue line) reconstituted mice. B, Representative flow 
cytometry plots of CXCR3 expression in TCRβ+ CD4+ Foxp3+ cells (top row) 
and CD44 (middle row) and IFNg (bottom row) expression in TCRβ+ CD4+ 
Foxp3- cells in Tcrb-/-Tcrd-/- mice reconstituted with the indicated bone marrow 
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Our fate-mapping studies during Listeria monocytogenes and LCMV 
challenge showed that bacterial or viral infections can serve as other 
independent sources for the generation of T-bet-expressing Treg cells from a 
distinct pool of precursor T-bet- Treg cells.  Fate-mapped T-bet-expressing 
Treg cells generated during infection maintained T-bet expression following 
pathogen clearance.  Significantly, these cells were preferentially activated 
during reinfection, as opposed to at steady state, whereas steady state-
generated T-bet+ Treg cells appeared to be preferentially activated at steady 
state, as opposed to infection.  These results were indicative of a further layer 
of heterogeneity within the T-bet+ Treg cell population. 
The continuous peripheral generation of T-bet+ Treg cells resulting in 
stability of T-bethi Treg cells implied a potentially specific function for T-bet+ 
Treg cells in immunological tolerance. Indeed, we found that both elimination 
of steady state T-bet+ Treg cells and their loss of function upon targeted Foxp3 
ablation resulted in a selective failure to restrain pronounced TH1-type T cell 
activation and associated severe autoimmune pathology.  In addition to 
suppressing steady state TH2 and TH17 autoimmune responses, mice 
depleted of T-bet+ Treg cells also efficiently regulated TH2 responses to N. 
brasiliensis, further suggesting that T-bet+ Treg cell function may be restricted 
to TH1 responses.  Although we cannot formally exclude the possibility that 
elimination of some ‘exT-bet’-expressing Treg cells in Tbx21RFP-CreFoxp3FL and 
Foxp3KO + Tbx21RFP-Cre/WTRosa26iDTR -> TcrbKOTcrdKO mice (due to transient 
Cre expression) contributed to the observed TH1 immune activation, the lack of 
exacerbated TH2 and TH17 responses both at steady state and following 
helminth infection in these mice argue strongly against a general deficiency in 
the Treg cell (or specifically effector Treg cell) compartment—which results in 
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non-specific TH1, TH2, and TH17 inflammation—and instead suggests that the 
Treg cell pool depleted of T-bet+ cells can efficiently control TH2 and TH17 but 
not TH1 responses. 
Notably, we found that T-bet, by itself, contributed only modestly to the 
ability of T-bet-expressing Treg cells to control TH1 responses and—consistent 
with previous reports—was dispensable for preventing disease.  As STAT1 
activation precedes and is required for T-bet expression in Treg cells induced 
upon IFNg or IL-27 signaling in different contexts and in different anatomical 
sites (Hall et al., 2012; Koch et al., 2012; Koch et al., 2009), it is likely that 
STAT1 and T-bet jointly contribute to some degree to T-bet+ Treg cell function.  
At the same time, it is possible that T-bet, in combination with STAT1, might 
continuously enforce its own expression, resulting in the stable T-bet+ 
phenotype. 
A recent study showed that IL-27 producing dendritic cells, which have 
been exposed to IFNg stimulation, are capable of inducing T-bet expression in 
Treg cells (Lee et al., 2015).  It seems reasonable to speculate that 
presentation of self-antigens by these dendritic cells induces T-bet and imparts 
the lasting T-bet expression in T-bethi Treg cells at steady state.  Indeed, our 
TCR sequencing results suggest that T-bet+ Treg cells possess a distinct TCR 
repertoire.  This observation together with our observations that a paucity of 
commensal microbiota resulting from treatment of mice with a cocktail of 
broad-spectrum antibiotics failed to diminish numbers of these cells are 
consistent with an idea that under physiologic conditions T-bet+ Treg cells are 
likely continuously generated in response to self, rather than microbial, 
antigens.  We suggest that in addition to T-bet-dependent CXCR3 expression, 
distinct TCR specificities of T-bet+ Treg cells may play an important role in 
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accumulation and activation-dependent suppressor function of T-bet+ Treg 
cells at sites of TH1 inflammation. 
TCR specificity may account in large part for the observed 
heterogeneity within the Treg cell population.  In this regard, new generation of 
T-bet-expressing Treg cells in response to Lm infection—rather than 
expansion of a pre-existent T-bet+ cell population—parallels differentiation of 
CD4 T cells into TH1 effectors, and was consistent with an antigen-dependent 
generation.  Furthermore, contraction of Lm-experienced Treg cells following 
resolution of the infection and preferential re-expansion of these cells following 
reinfection, albeit moderate in comparison to their effector counterparts, 
resembled antigen-specific effector CD4 T cell recall responses.  In this 
context, it is notable that we have observed T-bet+ Treg cell differentiation in 
response to Lm as well as LCMV infections in which Treg cells have not been 
shown to recognize known or surrogate pathogen-derived antigens (Ertelt et 
al., 2009; Shafiani et al., 2013; Srivastava et al., 2014).  Thus, it is possible 
that de novo generation of T-bet+ Treg cells during infection was potentially 
due to recognition of “pathogen-activated” self-antigens or steady state 
antigens differentially presented during infection.  The former likely supported 
the observed acquisition of T-bet expression by resting (“naïve”) T-bet- Treg 
cells whereas the latter may have promoted T-bet induction in activated 
CD44hi T-bet- precursors. 
In conclusion, our study suggests that heterogeneity of Treg cells may 
be a critical feature of immunological tolerance.  Peripheral Treg cells can 
differentiate into a highly stable T-bet-expressing population independently 
contributed to by acquisition of T-bet expression at steady state and during 
infectious challenge.  Our results suggest that under physiologic conditions 
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immunological tolerance may be maintained by polarized differentiation of 
Treg cells into an “effector-like” state with particular function concomitant with 
differentiation of polarized effector CD4 T cells. Such a mechanism may 
enable the adaptive immune system to coordinate potency of anti-
inflammatory and inflammatory responses to maintain a necessary balance. 
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Materials and Methods 
Animals 
Tbx21tdTomato-T2A-CreERT2 mice were generated upon insertion of the 
corresponding targeting construct into the Tbx21 locus by homologous 
recombination in embryonic stem cells (ESCs) on the C57BL/6 background; 
the targeting construct was generated by inserting sequence containing Exons 
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2-5 of the Tbx21 gene from BAC RP23-237M14 (BACPAC Resources Center) 
into a plasmid backbone containing a PGK promoter driving expression of 
diphtheria toxin A subunit (DTA) followed by BGHpA sequence (modified 
PL452 plasmid).  A SalI restriction enzyme site was simultaneously 
engineered into the Tbx21 3’UTR between the stop codon and the 
polyadenylation site.  The Clontech Infusion HD Cloning system was used to 
generate in the pUC19 plasmid backbone sequence containing (in order from 
5’ to 3’) encephalomyocarditis virus IRES; tandem dimer (td) Tomato; T2A 
self-cleaving peptide from Thoseaasigna virus; Cre recombinase fused to the 
estrogen receptor ligand binding domain (ER); followed by a frt site-flanked 
PGK-Neomycin resistance gene (NEO)-BGHpA cassette.  The IRES-
tdTomato-T2A-CreERT2-frt-NEO-BGHpA-frt sequence was PCR-amplified 
and inserted into the SalI site in the Tbx21 3’UTR in the modified PL452 
backbone.  The resulting plasmid was linearized with the restriction enzyme 
NotI prior to electroporation into ESCs.  Tbx21tdTomato-T2A-Cre mice were 
generated similarly, with Cre recombinase containing a nuclear localization 
sequence replacing the CreERT2 sequence.  Tbx21tdTomato-T2A-CreERT2 and 
Tbx21tdTomato-T2A-Cre mice were bred to FLPeR mice to excise the NEO cassette 
and backcrossed to C57BL/6 mice to remove the FLPeR allele. 
 
Foxp3Thy1.1, R26Y, Foxp3FL, Foxp3KO, RorcGFP, Foxp3YFP-Cre, IL-10eGFP, and 
Tbx21FL mice have been previously described (Eberl et al., 2004; Fontenot et 
al., 2003; Intlekofer et al., 2008; Kamanaka et al., 2006; Liston et al., 2008; 
Rubtsov et al., 2008; Srinivas et al., 2001).  CD45.1, Rosa26iDTR, and TcrbKO 
mice were purchased from Jackson Laboratories.  Generation and treatments 
of mice were performed under protocol 08-10-023 approved by the Sloan 
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Kettering Institute (SKI) Institutional Animal Care and Use Committee. All 
mouse strains were maintained in the SKI animal facility in specific pathogen 
free (SPF) conditions in accordance with institutional guidelines. 
 
For tamoxifen administration, 40 mg tamoxifen dissolved in 100 μl ethanol 
and subsequently in 900 mL olive oil (Sigma-Aldrich) were sonicated 4 × 30 
seconds in a Bioruptor Twin (Diagenode). Mice were orally gavaged with 
200μl tamoxifen emulsion per treatment. For diphtheria toxin (DT) injections, 
DT (Sigma-Aldrich) was dissolved in PBS and 200 μl of indicated doses were 
injected i.p per mouse.  For antibiotic treatment, 0.5 g Ampicillin, 0.5 g 
Kanamycin, 0.4 g Vancomycin, 0.5 g Metronidazole, and 7 packets of 
SplendaTM sweetener were dissolved in 500mL of water and filter sterilized.  
Mice were weaned onto antibiotic-treated water, which was changed once a 
week until the time of analysis. 
 
Isolation of cells 
Spleens and lymph nodes were dissociated using ground glass slides and 
filtered.  Red blood cells in spleens were lysed before analysis.  For analysis 
of YFP-labeled CD4 T cells in Tbx21RFP-CreERT2 mice, CD4 T cells in spleens 
and lymph nodes were enriched using the Dynabeads CD4 Positive Isolation 
Kit (Invitrogen).  To isolate lymphocytes from tissues, mice were euthanized 
and immediately perfused with 20 mL PBS.  Small and large intestines were 
removed, flushed with PBS, Peyer’s patches were removed, and residual fat 
and connective tissue was removed.  Intestines were opened lengthwise and 
cut into 0.5 cm-long pieces that were further washed by vortexing in PBS.  
Samples were incubated in PBS supplemented with 5% fetal calf serum, 1% L-
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glutamine, 1% penicillin-streptomycin, 10 mM HEPES, 1 mM dithiothreitol, and 
1 mM EDTA for 15 minutes to dissociate intraepithelial lymphocytes, which 
were discarded.  Samples were washed and incubated in digest solution 
(RPMI supplemented with 5% fetal calf serum, 1% L-glutamine, 1% penicillin-
streptomycin, 10 mM HEPES, 1 mg/mL collagenase, and 1 U/mL DNase I) for 
10 minutes.  Cells were collected through a 100-μm strainer, and the residual 
samples were incubated in digest solution again for 10 minutes before filtering 
through 100-μm strainers and combining with previously collected cells.  Cells 
were resuspended in 35% Percoll to eliminate debis before resuspension in 
staining buffer.  To isolate lymphocytes from livers and lungs, tissues were 
physically dissociated using scissors and incubated for 50-60 minutes in digest 
solution before being filtered through 100-μm strainers.  Lungs samples were 
resuspended in 35% Percoll to eliminate debris before resuspension in 
staining buffer.  Lymphocytes from liver samples were resuspended in 44% 
Percoll, underlaid with 67% Percoll, and spun at 1000xg for 7.5 minutes at 
room temperature.  Cells were collected from the interface of the Percoll layers 
and washed before resuspension in staining buffer. 
 
Nippostrongylus brasiliensis infection 
Nippostrongylus brasiliensis (Nb) was maintained by passage in 9 to 10 week-
old Wistar rats as previously described (Camberis et al., 2003).  Briefly, rats 
were injected subcutaneously (s.c.) with 7000 L3 Nb and stool was collected 
on days 6-9 post infection.  Fecal pellets were mixed with 5x8 bone charcoal 
and incubated on moisten filter paper in petri dishes at 26°C for 7 days. L3 
larvae were recovered from the edge of the filter paper and the perimeter of 
the plates and extensively washed with PBS to eliminate contaminants before 
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infection.  Mice infections were carried out using a 23G needle at a 
concentration of 500 L3 Nb in 200 μL. 
 
Listeria monocytogenes infection 
For Listeria monocytogenes (Lm) infections, frozen stocks were thawed, 
resuspended in Brain-Heart Infusion media, and grown at 37oC to an OD600 of 
0.1.  For primary infections, mice were injected via lateral tail vein with 5–
10x103 colony-forming units (cfu) of Lm diluted in 200 µL PBS.  For secondary 
infection, mice were injected via lateral tail vein with 105 cfu of Lm in 200 µL 
PBS. 
 
Cell transfer experiments 
For cell transfer experiments, pooled spleens and lymph nodes were enriched 
for CD4 T cells using the Dynabeads CD4 Positive Isolation Kit.  Cells were 
FACS-sorted on an Aria II cell sorter (BD Bioscience), washed 3 times in PBS, 
resuspended in 200 µL PBS, and transferred into recipients via retro-orbital 
injection.    
 
Generation of bone marrow chimeric mice 
Tcrb-/-Tcrd-/- recipient mice were lethally irradiated with 650 Gy.  The following 
day, bone marrow was isolated from femurs of donor mice and depleted of T 
cells and RBCs via staining with biotinylated anti-Thy1.2 and anti-Ter119 
antibodies followed by magnetic bead negative selection.  5x106 total T cell-
depleted bone marrow cells were transferred into recipient mice via retro-
orbital injection.  
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Flow cytometric analysis 
Cells were stained with LIVE/DEAD Fixable Yellow Dead Cell Stain (Molecular 
Probes) and the following antibodies purchased from eBioscience, BioLegend, 
BD Biosciences, Tonbo, or obtained from the NIH tetramer core facility: anti-
CD4 (RM4-5), anti-CD8a (5H10), anti-TCRβ (H57-597), PBS-57-loaded 
mCD1d tetramer, anti-Thy1.1 (HIS51), anti-CD44 (IM7), anti-CD62L (MEL-14), 
anti-CXCR3 (CXCR3-173), anti-CD25 (PC61), anti-CTLA-4 (UC10-4B9), anti-
GITR (DTA-1), anti-CD39 (24-DMS1), anti-Foxp3 (FJK-16s), anti-T-bet (4B10), 
anti-RORγt (B2D), anti-Gata-3 (TWAJ), anti- IFNg (XMG1.2), anti-IL-4 
(11B11), anti-IL-17A (17B7), and anti-IL-2 (JES6-5H4).  Flow cytometric 
analysis was performed using an LSRII flow cytometer (BD Bioscience) and 
FlowJo software (Tree Star). Intracellular staining was performed using 
eBioscience Fixation Permeabilization buffers. For cytokine staining 
lymphocytes were stimulated with soluble anti-CD3 clone 2C11 (5μg/ml) and 
anti-CD28 clone 37.51 (5μg/ml) in the presence of 1μg/mL brefeldin A for 5 
hours at 37°C, 5% CO2. 
 
RNA-seq analysis 
Pooled spleens and lymph nodes were enriched for CD4 T cells using the 
Dynabeads CD4 Positive Isolation Kit.  CD4+Thy1.1+ cells were FACS-sorted 
on an Aria II cell sorter (BD Bioscience) into 4 populations 
(CD62LhiCD44loRFP-, CD44hiRFP-, CD44hiRFPloCXCR3-, and 
CD44hiRFPhiCXCR3+ cells) and resuspended in Trizol.  Three replicates of 
each cell subset were generated.  RNA-sequencing reads were aligned to the 
reference mouse genome GRCm38 using the Burrows-Wheeler Aligner (BWA) 
(Li and Durbin, 2010) and local realignment was performed using the Genome 
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Analysis Toolkit (GATK) (McKenna et al., 2010). For each sample, raw count 
of reads per gene was measured using R, and DESeq2 R package (Love et 
al., 2014) was used to perform differential gene expression among different 
conditions. A cutoff of 0.05 was set on the obtained p values (that were 
adjusted using Benjamini-Hochberg multiple testing correction) to get the 
significant genes of each comparison. 
 
TCR sequencing and data analysis 
Briefly, following isolation of CD4+ T cells from spleens and lymph nodes of 
DO11.10 TCRβ transgenic Tcra+/- Foxp3DTReGFP mice using the Dynabeads 
CD4 Positive Isolation Kit (Invitrogen), CD44hiCXCR3- and CD44hiCXCR3+ 
eGFP(Foxp3)+ Treg and eGFP- effector CD4 T cells were FACS sorted and 
stored in Trizol.  TCR sequencing and data analysis were performed as 
previously described (Feng et al., 2015).  Pearson correlation of clonotype 




All statistical analyses (excluding RNA-seq and TCR sequence analyses, 
described above) were performed using GraphPad Prism 6 software.  
Differences between individual groups were analyzed for statistical 
significance using the unpaired or paired two-tailed Student’s t-test. *, p ≥ 0.05; 
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 CHAPTER 5 
CONCLUSION 
 
In our studies, we have attempted to address how Treg cells generated in the 
thymus mature in the periphery and suppress autoimmune responses.  Our 
results suggest that Treg cell maturation and function is elicited and organized 
in a manner similar to that of conventional effector CD4+ T cells.   
 Akin to effector CD4+ T cells, Treg cells emerge from the thymus as 
naïve CD44loCD62Lhi cells and subsequently undergo effector differentiation 
into CD44hiCD62Llo cells in the periphery through a TCR-dependent process, 
which in Treg cells is likely driven by self-antigen recognition.  Following 
peripheral maturation into a Treg cell population consisting of effector as well 
as naïve cells, Treg cells continue to require the TCR for suppression of 
autoimmunity, much as effector CD4+ T cells require TCR engagement for 
cytokine production and elaboration of effector functions against invading 
pathogens.  Consequently, inducible deletion of the TCR in Treg cells in adult 
mice resulted in rapid autoimmune activation.  Although in our experiments it 
was not possible to discriminate between the TCR-dependent functions of 
effector versus naïve Treg cells, our finding that loss of the TCR dramatically 
affected gene expression specifically in the effector Treg cell subset 
suggested that a significant portion of suppressive function may be confined to 
the effector Treg cell pool at steady state.  However, it is also likely that naïve 
Treg cells may inhibit certain aspects of autoimmunity in a TCR-dependent 
manner, such as priming of analogously naïve yet autoreactive CD4+ T cells.  
 In regards to Treg cell TCR specificity, our experiments switching the 
endogenous Treg cell TCR repertoire for predominantly a single specificity 
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suggested that, to an extent, TCR-dependent function could be maintained in 
the absence of diverse and developmentally established specificities.  
However, suppression by such a monoclonal Treg cell compartment was also 
notably limited, indicating the importance of specificity and diversity for 
comprehensive control of spontaneously induced autoimmunity and 
inflammation by Treg cells. 
 We also found that, like some conventional CD44hi CD4+ T cells that 
stably express the TH1 specifying transcription factor T-bet and produce IFNγ 
at steady state, a portion of regulatory T cells likewise stably expressed high 
amounts of T-bet.  Both effector CD4+ and Treg cell compartments underwent 
a continuous process of differentiation at steady state whereby some 
percentage of T-bet- cells gradually up-regulated T-bet to ultimately achieve 
high and stable expression of the transcription factor, which was not lost even 
in strongly TH2 polarizing conditions resulting from helminthic infection.  Just 
as conventional CD4+ T cells responded to intracellular bacterial and viral 
infections by differentiating into CD44hi effectors that expressed T-bet, both 
Listeria monocytogenes and LMCV infections induced T-bet expression in a 
subset of Treg cells.  Moreover, re-expansion of Listera-induced T-bet+ 
effector CD4+ T cells during re-challenge was accompanied by a concomitant 
re-expansion of Listeria-induced Treg cells, demonstrating in this instance a T-
bet+ Treg cell recall response mirroring that of effector cells.   
 These results suggested that T-bet+ Treg cells induced at steady state 
might regulate T-bet+ effector CD4+ T cells induced at steady state, while T-
bet+ Treg cells induced by pathogenic challenge might regulate T-bet+ effector 
CD4+ T cells induced by that same pathogen.  Indeed, we found that 
wholesale elimination of T-bet+ Treg cells—but not of T-bet itself—at steady 
  151 
 
state unleashed a selectively TH1 autoimmunity that was driven by T-bet+ αβ T 
cells.  Together, these results indicate that immunological tolerance may be 
maintained through a TCR-dependent process of parallel differentiation of 
Treg cells into polarized effector states concomitant with differentiation of 
conventional CD4+ T cells into polarized effectors, occurring both at steady 
state and during infectious episodes.  Such a mechanism may enable the 
adaptive immune system to coordinate potency of anti-inflammatory and 
inflammatory responses to maintain a necessary balance. 
 
